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Abstract 
The purpose of this dissertation was to explore how the anxiety levels of non-Hodgkin’s 
lymphoma patients receiving chemotherapy are affected while holding hands with a secure 
attachment.  This study utilized three experimental single-case designs: participant one measured 
under a B-design, participant two measured under a B-A design, and participant three measured 
under an A-B design.  Each participant’s anxiety was assessed during six chemotherapy 
treatments and one meeting with their primary oncologist to discuss the prognosis of their 
cancerous disease.  Results visually indicate a greater effect on anxiety reduction during 
treatment when the intervention is utilized compared to only having a secure attachment present.  
Visual analysis revealed a reducing trend in anxiety for participant one when holding hands.  
Participants two and three’s anxiety continued to decline while holding hands throughout 
treatments but increased when hand holding was removed.  Follow-up interviews of all three 
participants support the positive effects hand holding had on anxiety reduction during treatment.  
The results of this study may inform mental health professionals and oncology care teams 
consulting cancer patients about effective coping interventions against anxiety experienced 
during treatment.  Future research should replicate this study focusing on single-case reversal 
designs.      
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The Effects of Hand Holding on Cancer Patients Level of Anxiety: A Single-Case Study  
CHAPTER I: 
INTRODUCTION 
In 2016, Armitage, Gascoyne, Lunning, and Cavalli (2017) estimated that 72,580 cases of 
non-Hodgkin’s lymphoma would be diagnosed in the United States.  The American Cancer 
Society (2018) has estimated that 74,680 people (41,730 males and 32,950 females) will be 
diagnosed with non-Hodgkin’s lymphoma and 19,910 people will die from the disease in 2018.  
Factors such as immune disorders, medicines, infections, lifestyle, genetics, race, family history, 
and occupation impact an individual’s risk of developing non-Hodgkin’s lymphoma (Armitage et 
al., 2017).  After the diagnosis of non-Hodgkin’s lymphoma, patients typically have a five-year 
survival rate of 70% and a ten-year survival rate of 60% (American Cancer Society, 2016b).  
Depending on the type, grade, and stage of a patient’s non-Hodgkin’s lymphoma, patients are 
either administered a current curative intent treatment regimen such as chemotherapy, given a 
stem cell transplant, or even the use of a surgical procedure (American Cancer Society, 2016b).  
However, these treatments create physical and psychological side effects throughout and after 
completion (Adler & Page, 2008; American Cancer Society, 2016a).  Khalil et al. (2016) 
revealed that 48.7% (N = 300) of general cancer patients suffer from anxiety throughout 
treatment.  Chemocare (2018) explains that anxiety among cancer patients may consist of 
uneasiness, nervousness, worry, or fear in relation to cancer.  Oerlemans et al. (2014) revealed 
that 10% (N = 489) of non-Hodgkin’s lymphoma patients reported that they were always anxious 
or depressed, and 15% reported feeling anxious or depressed some of the time for the duration of 
their treatment.  Further, Oerlemans et al. (2014) have indicated that up-to-date research is 
exceeding 15 years when focusing on anxiety and depression reduction interventions among 
lymphoma patients.  However, research has found that some forms of physical comfort can 
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ameliorate anxiety among non-Hodgkin’s lymphoma patients.  Moon and Cho (2001) reported 
that physical touch provides beneficial outcomes in anxiety reduction for cancer patients.  
Specifically, they found that holding hands is a form of physical touch comfort that reduces 
anxiety (Moon & Cho, 2001).  In addition to physical touch, the physical presence of another 
person can provide comfort, when that support is based on a secure attachment.   
As a secure attachment is necessary for an individual’s psychological wellbeing 
(Ainsworth, 1973; Bowlby, 1969), interventions of physical touch, such as holding hands, can 
aid in reducing anxiety (Moon & Cho, 2001).  A secure attachment, as defined in this study, is 
the enduring emotional bond that one person feels with another, which results in the ability to 
manage anxiety.  Johnson et al. (2013) explained that holding hands with an individual to whom 
one is securely attached may contribute to a reduction in their perception of significant threat-
related brain activation.  The bond of a secure attachment limits the neural activity a patient 
experiences (Johnson et al., 2013), which may allow the patient to experience lower levels of 
threat and anxiety.  This neural activity links to the body’s immune system responses; therefore, 
limiting neural activity helps the body’s adaptive immune system react more efficiently to cancer 
treatment (Parham, 2009).  Parham (2009) clarified that reduced anxiety aids in the body’s 
physical adaptation to cancer treatment.  This study, therefore, will address the relationship 
between secure attachment and daily hand holding in relation to anxiety among non-Hodgkin’s 
lymphoma patients.  
Statement of the Problem 
Although most individuals adapt well when experiencing change in their life, a cancer 
diagnosis may negatively impact the emotional well-being and quality of life of a patient, a 
patients family, and even caregivers (American Cancer Society, 2016b).  Further, cancer patients 
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and cancer survivors may feel distress about the future even years after the cancer is treated 
(American Cancer Society, 2016b).  The fear of treatment, frequent visits to medical clinics or a 
hospital, and undergoing continual tests may create more anxiety for the patient by thinking 
something bad and unknown is going to happen (American Cancer Society, 2016b).   
As previously mentioned, a variety of side effects associated with the diagnosis and 
treatment of cancer can negatively impact patients and their family members even after treatment 
is completed (Adler & Page, 2008, American Cancer Society, 2016b).  In addition to the fact that 
the longevity of chemotherapy sessions may cause damage to the body and its functions 
(American Cancer Society, 2016a), research suggests that patient’s experience higher levels of 
stress and anxiety during chemotherapy treatments (Barre, Padmaja, Saxena, & Rana, 2015).  
Depending on the type of diagnosis, treatment regimen, and future prognosis, these patients are 
susceptible to experience heightened emotional and mental health problems (Adler & Page, 
2008).  Further, the patient’s own experienced anxiety throughout the diagnosis and over the 
course of treatments can cause fear and anxiety for their caregivers in relation to losing their 
loved ones, thus creating a cycle of negative emotions for both the patient and caregiver (Adler 
& Page, 2008).  Post diagnosis, the psychological side effects of non-Hodgkin’s lymphoma can 
affect patients’ overall wellbeing, future outlook, and relationships with others (Adler & Page, 
2008).  These negative emotions can develop overtime and create symptoms that mimic or even 
classify as post-traumatic stress disorder.  The American Psychiatric Association’s Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) explains that experiencing a life 
threatening medical illness or even observing it in another can contribute to the future signs of 
post-traumatic stress disorder (PTSD; American Psychiatric Association, 2013).  Therefore, 
active engagement through holding hands with an individual with whom they are securely 
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attached (in this case, a caregiver) may prove useful for both patients and caregivers in managing 
the effects of cancer. 
Interventions for mental and emotional effects remain limited during non-Hodgkin’s 
lymphoma treatment.  Research specifically focuses on the need for interventions to treat patient 
anxiety (Barre et al., 2015).  Maresh, eBeckes, and Coan (2013) measured both state and trait 
anxiety; their research indicates that the role of social support through holding hands regulates 
emotional responses in anxious individuals.  State anxiety is described as an unpleasant 
emotional stimulation in threatening demands or dangers (Schwarzer, 1997).  Lazarus (1991) 
explains a threat must be experienced for the mind to appraise this emotion.  Trait anxiety, 
however, reflects the presence of established individual variances in response with state anxiety 
in the expectation of threatening situations (Schwarzer, 1997).  Additionally, Oh and Park (2004) 
found that both hand massage and hand holding are effective nursing interventions contributing 
to psychological and physiological anxiety alleviation for patients undergoing local infiltration 
anesthesia.  Similarly, a phenomenological study of cancer patients undergoing treatment 
revealed that hand holding was a distraction from treatment, a source of security, and reduced 
pain through patients feeling more secure (Weekes, Kagan, James, & Seboni, 1993).  Moreover, 
Weekes’ et al. (1993) research explained that hand holding during treatment should be further 
studied utilizing qualitative and quantitative measures to explore the effects of hand holding 
within the realm of a patient’s family.   
Hand holding as an intervention to manage anxiety has not been limited to the population 
of cancer patients undergoing treatment.  Pirbudak and Tepe (2017) introduced hand holding in 
the context of gynecology procedures at the single case level, and all participants displayed 
positive effects in terms of pain and anxiety.  Similarly, Ergott (2008) described a birthing 
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experience in which vital signs were alarmingly low raising concern.  Despite the efforts of the 
medical staff, Ergott (2008) believes it was the strength drawn from hand holding of the nursing 
staff that kept the mother alive throughout delivery.  Based on the aforementioned research, the 
non-invasive intervention of holding hands during medical treatment appears to create a 
reasonable belief in effectiveness to relieve patient anxiety.   
Purpose of the Study 
The purpose of this dissertation was to explore how the anxiety levels of non-Hodgkin’s 
lymphoma patients receiving chemotherapy are affected while holding hands with a secure 
attachment.  Further, this study’s results focus on the effectiveness of hand holding as an 
intervention across various single-case designs to explore appropriate needs in the development 
of future experimental designs.  Many cancer patients seek the guidance of mental health 
professionals to learn coping skills given the effects of the diagnosis and treatments.  This 
dissertation strives to assist patient’s mental health and educate mental health professionals as 
patients are treated.  The following research question provided the focal point for this study: 
How does holding hands with a secure attachment impact a non-Hodgkin’s lymphoma patients 
(N = 3) anxiety, as measured by the State Trait Anxiety Inventory (Speilberger et al., 1983).  
Based on the results, the researcher discusses an agenda for future experimental design research 
integrating effective interventions for various cancer patients of appropriate diseases utilizing a 
secure attachment and hand holding.   
Significance of the Study 
The results from this study seek to enrich the psychological care of non-Hodgkin’s 
lymphoma patients through the intervention of hand holding during the treatment of non-
Hodgkin’s lymphoma.  Specifically, this study explores the anxiety levels of non-Hodgkin’s 
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lymphoma patients undergoing chemotherapy and how the expression of a secure attachment 
(psychological) via hand holding (physical) influences anxiety.  Adler and Page (2008) indicated 
the lack of research related to the negative experienced mental and emotional effects of cancer 
treatment on both patients and caregivers during treatment.    
It was necessary to employ various single-case designs given the specific population 
selected and the difficulty keeping a patient’s timeline of treatment consistent.  A non-Hodgkin’s 
lymphoma patient’s treatment and procedures vary on many factors including but not limited to: 
age, type of non-Hodgkin’s lymphoma, grading, staging, and reaction to the treatment.  Thus, the 
use of various single-case designs may provide specific contributions to this field.  In addition, 
Ray (2015) stressed the importance of and need for more single-case research and noted that this 
method has been recognized as a valuable approach dating back to the work of experimental 
psychologists in the 1880s.  The single-case design allows for detailed results for the individual 
in the study.  Adler and Page (2008) discussed the issues of generalizable results, such as 
available brochures educating patients about their disease, not conforming to the needs of each 
patient.  Thus, the goal of this study is to find more specifics, on a case-by-case basis, through 
the various single-case designs.  Based on these individual details, this study supports the need 
for additional studies and discussions on secure attachment relationships using hand holding as 
an intervention during cancer treatment.   
This study was designed to be easily replicated.  Specifically, one may utilize any 
available local oncology department treating non-Hodgkin’s lymphoma patients, follow the 
instructions within the assessment used, and adhere to the data collection procedures described to 
assist in accurate and replicable research for evaluating the effectiveness of hand holding as an 
anxiety reduction intervention among cancer patients.  Further, the study was focused on the 
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individual level, which places emphasis on the reasonable effects of the intervention.  The 
researcher hopes that this study can guide oncology settings to implement this intervention 
across the treatment of cancer patients.   
Definition and Operational Terms 
For the purposes of this study, the following definitions will apply: 
1. Secure Attachment is the enduring emotional bond that a person feels with another that 
results in the ability to manage anxiety (Ainsworth, 1973; Bowlby, 1969).  To avoid 
confusion, the definition should be read and used in the right context provided by 
Ainsworth (1973) and Bowlby (1969).  For the purposes of this study, the term secure 
attachment refers to the individual the non-Hodgkin’s lymphoma patients selected to 
attend treatments with them.    
2. Hand holding refers to the intervention used within the study.  Specifically, this term 
refers to the action being administered during the intervention phase to compare the 
baseline phase where hand holding is absent.  The non-Hodgkin’s lymphoma patient will 
hold the non-dominant hand of the secure attachment during chemotherapy treatment.  
Scores of the STAI (Speilberger et al., 1983) serve as the operational definition in 
accessing the effectiveness of hand holding as an intervention for alleviating anxiety 
during non-Hodgkin’s lymphoma treatment.    
3. CT scan meeting refers to the Computed Tomography Scan that non-Hodgkin’s 
lymphoma patients receive to determine diagnosis before treatments and prognosis 
measured at the oncologist’s discretion.  
Assumptions of the Study 
There are many assumptions implicit within this study.  First, the researcher assumes that 
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each patient was required to follow the directed treatment regimen and procedures outlined by 
their primary oncologist.  Second, the researcher assumes that results vary depending on the 
safety and security of relationships between the cancer patient and his or her social and / or 
caregiving network.  Third, the researcher assumes the cancer patients involved in the study have 
differing demographics and attributes, since non-Hodgkin’s lymphoma can be diagnosed within 
diverse populations.  Fourth, the researcher assumes that hand holding with a secure attachment 
can lead to decreased anxiety levels throughout treatment.  Fifth, the researcher assumes the 
cancer patients participating in this study have answered all questions honestly and without bias.  
Sixth, the researcher assumes that the participants completed the Participant Screening Form  
(Appendix D) honestly.  The Participant Screening Form (Appendix D) acts as an assessment to 
specifically rule out the chance of a patient feeling anxious while holding hands with a secure 
attachment.  For more details regarding the specifics of the secure attachment, or hand holding 
and anxiety, see the Participant Screening Form (Appendix D).  Seventh, the researcher assumes 
that the secure attachment follows the Secure Attachment Protocol Form (Appendix E) 
accurately, and if deviation were to occur, that the secure attachment noted specifics within the 
Post Session Questionnaire (Appendix F).  Finally, the researcher assumes that the obtained data 
is valid and reliable.  These assumptions direct the results and discussion section, and were 
evaluated throughout the course of the study.   
Delimitations 
This study was conducted among patients who have been diagnosed with non-Hodgkin’s 
lymphoma at a mid-south oncology department.  Patients diagnosed in stages one through four of 
this disease were admitted into the study.  According to the American Cancer Society (2016b), a 
patient is said to have good prognostic factors if they meet the following classifications: be 60 
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years of age or younger, and be diagnosed within stages one or two.  Patients who display poor 
prognostic factors are 60 years of age or older, and are diagnosed with stages three or four 
(American Cancer Society, 2016b).  For the purposes this study, inclusion criteria was not 
sensitive to staging of the disease, but that the patient be diagnosed with non-Hodgkin’s 
lymphoma.  For more details regarding acceptance, see the Participant Screening Form 
(Appendix D).   
Next, a patient could not have an existing anxiety-related, DSM-V-diagnosed mental 
disorder.  This diagnosis would indicate the participant already had a high anxiety level, 
potentially even in the presence of the caretaker.  Further, preexisting anxiety may have been 
related to a prior past life event.  Thus, to allow for more clear results, these individuals were not 
accepted into the study.  A participant could not have any physical conditions related to past 
cancer treatment.  If the participant had previously experienced the chemotherapy process by 
receiving treatment, this may impact the results and may not allow for true measures.  Some 
accepted participants may have experienced cancer through a relative or friend; this did not 
impact their acceptance into the study.  Lastly, per the Participant Screening Form (Appendix D), 
only patient’s who had a secure attachment were allowed into the study.  Each individual 
experiences the treatment process differently.  Therefore, within the research design, the 
researcher aimed to accommodate the uniqueness of each participant.  The researcher chose a 
single-case research design over other designs in order to highlight the uniqueness of each 
individual in treatment, and because there are a limited amount of treatments for non-Hodgkin’s 
lymphoma, and a single-case study research design helps differentiate what interventions work 
with certain individuals, in certain conditions (Ray, 2015). 
It is not within the scope of this study to identify whether an individual’s physical 
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presence in the room, or communication with a patient has an effect on anxiety, but rather to 
draw specific conclusions about a patient’s anxiety levels.  Participants receiving treatment must 
have been given a diagnosis of non-Hodgkin’s lymphoma.  The primary variable of debate, 
though not limited to, is that a participant’s anxiety decreased as the result of the presence of a 
secure attachment during treatment.  This may reduce the significant impact hand holding has on 
anxiety.  Therefore, participants meeting criteria were selected based on the date of their 
prognosis meeting.  The prognosis meeting was an appointment where each participant 
completed with their primary oncologist to review the results of their Computed Tomography 
Scan (CT scan meeting) and determine a prognosis.  Participant one served as a monitor of 
intervention effectiveness across all measures, and if the intervention was meaningful.  Thus, 
participant one completed five chemotherapy measures, then the CT scan meeting, and then the 
final chemotherapy measure while holding hands with a secure attachment.  This control allowed 
the researcher to track the effectiveness of hand holding for this participant and to see if the CT 
scan meeting influences the results.  Given the positive results of the hand holding intervention, 
the study was changed for participants two and three to use phase randomization to assist in 
controlling the aforementioned confounding variables (Onghena & Edgington, 2005), such as the 
CT scan meeting.  The CT scan meeting for participant two and three were measured first, 
followed by the six chemotherapy measures to see if this trend would continue across 
participants.  Controlling when the chemotherapy measures began allowed the researcher to draw 
more specific conclusions about the effectiveness of hand holding with a secure attachment 
during treatment.  Additionally, participant two was selected to undergo the intervention of hand 
holding for the CT scan meeting and the first three chemotherapy measures and then measuring 
the last three without holding hands.  Participant three underwent the CT scan meeting and first 
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three chemotherapy measures without holding hands and then measured the last three while 
holding hands.  This structure allowed the researcher to differentiate between the potential 
effects of the secure attachments presence from the effects of holding hands during treatment.   
This study was not conducted with individuals going through treatment without a secure 
attachment, due to the lack of emotional connection while holding hands may skew the results.  
Cancer patients’ anxiety levels were measured during chemotherapy to ensure this study’s 
effectiveness.  It is important to note that the participants’ secure attachments were responsible 
for scoring the assessment, as the researcher was not able to attend each participant’s 
chemotherapy sessions.  The accuracy of responses was assessed within the Post Session 
Questionnaire (Appendix F).  The secure attachment functioned as an additional participant in 
the study, completing all necessary consent.  The secure attachment also completed a Post 
Session Questionnaire (Appendix F) to describe any deviation from the Secure Attachment 
Protocol Form (Appendix E), if the cancer participant deviated from the treatment routine, or if 
external circumstances hindered authentic responses to the STAI (Speilberger et al., 1983). 
Summary 
 The aim of this study was to increase research related to the reduction of anxiety for non-
Hodgkin’s lymphoma cancer patients by identifying the effects of hand holding at the single-case 
level.  It provides evidence that supports hand holding as an effective intervention in anxiety 
reduction for non-Hodgkin’s lymphoma.  The benefit of a single-case design is the small sample 
size, and that it allows each participant to function as their own control, compared to the 
intervention measurements (Ray, 2015).  This chapter addressed the current gap in literature with 
respect to hand holding as a form of physical touch intervention to ameliorate anxiety among 
non-Hodgkin’s Lymphoma patients, as well as the direction for this study.  Chapter two will 
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provide a literature review comprising more research that supports this study.    
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CHAPTER II:  
LITERATURE REVIEW 
The process of chemotherapy can create negative physical and mental effects. Within this 
chapter, the researcher reviewed literature on the development of human connection through 
physical touch, beginning in the work of Hippocrates and continuing to present day forms of 
physical touch and its effects.  Moreover, research was outlined on the types of physical touch 
and the effects of physical touch in its various forms.  Second, the researcher provided an 
evaluation of anxiety with a focus on the psychological issues that may be present throughout 
treatment.  Additionally, literature on cancer patients’ quality-of-life as a result of the anxiety 
present in treatment was discussed.  Third, the researcher identified relationship attachment 
through the following constructs: an overview of relationship attachment and its effects; 
neuroscience with relationship attachment; and an overview of the relationship attachment styles 
based on attachment theory.  Fourth, the history of lymphoma was explored.  This chapter 
concludes with a brief summary to explain how the importance of physical touch through a 
secure attachment during chemotherapy may have a greater impact on a lymphoma patient 
psychologically than extant research has yet addressed. 
Method of Systematic Review 
The researcher compiled the information for this literature review from the following 
databases: EBSCO Host, PsychINFO, ProQuest, and UpToDate Databases.  The following 
keywords were used either individually or in conjunction with one another: “physical touch,” 
“hand holding,” “relationship attachment,” “cancer,” “lymphoma,” “anxiety,” and “immune 
system.” Additionally, print sources such as books and articles were provided by oncologists at a 
mid-south cancer treatment facility, advising professors, and university library personnel.  
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Finally, the researcher purchased State-Trait Anxiety Inventory for each patient’s treatment 
measurement. 
Lymphoma 
History of Lymphoma  
Lymphoma can be described as a tumor of lymphocytes that grow within the lymph 
nodes and other tissues; the malignant lymphocytes are not able to enter the blood in sizeable 
numbers (Parham, 2009).  Additionally, lymphoma can be understood as a cancer that starts in 
cells in association with the body’s immune system (American Cancer Society, 2016).  There are 
two primary types of lymphoma: Hodgkin’s Lymphoma (named after Dr. Thomas Hodgkin, who 
first discovered the disease) and non-Hodgkin’s Lymphoma.  Hodgkin’s lymphoma is frequently 
discovered in adolescents and older adults, and accounts for 10% of cancers diagnosed annually 
(Jacobs & Harvey, 2013).  Approximately 92% of Hodgkin lymphoma patients have a one-year 
survival rate at the stage of prognosis (American Cancer Society, 2014).  Non-Hodgkin’s 
lymphoma (NHL) has been studied as the most common hematological malignancy in the world 
(Limat et al., 2014) and is the seventh most common cancer in North America, with a frequency 
that has risen 15% throughout the past two decades (Lin et al., 2014).  Brenner, Gondos, and 
Arndt (2007), have reported  that since the 1980s, the long-term prognosis of NHL has improved.  
Advances have been made in chemotherapy treatment regimens that attack the disease 
aggressively (Limat et al., 2014).   
The following constructs will be discussed in more detail in order to better understand 
lymphoma: function of lymph nodes, development of lymphoma, treatment, and the physical and 
psychological effects of treatment.   
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Function of Lymph Nodes 
The immune system is vital in the treatment of lymphoma, as the disease affects the lymph 
nodes.  The lymph node is one of the important sites in the human body where “immune 
responses to pathogenic antigens are initiated” (Buettner & Bode, 2012, p. 205).  As the lymph 
nodes engage a foreign agent of the body, a process occurs, which Buettner and Bode (2012) 
described as a migration of cells from one receptor to antigens for effective antibody production.  
This precise migration is possible because of homing molecules that are up-regulated on effector 
cells after activation. (Buettner & Bode, 2012, p. 205)  If this migration process does not 
function at capacity, complications such as lymphoma can arise.  
Development of Lymphoma and Treatment Options  
 
For a cancer cell to be deemed successful and/or life threatening, it must consist of seven 
core principles.  Parham (2009, p. 494) has developed a list of these principles:  
1. Cancer cells stimulate their own growth 
2. Cancer cells ignore growth-inhibiting signals from other cells 
3. Cancer cells avoid death by apoptosis 
4. Cancer cells connect to the blood 
5. Cancer cells invade other tissues  
6. Cancer cells inexorably expand to the size of their population 
7. Cancer cells outwit the immune system to survive 
When treating non-Hodgkin’s lymphoma, there are many options dependent of the type, 
grade, and stage of the disease.  Options can include chemotherapy, immunotherapy, targeted 
therapy drugs, high-dose chemotherapy and stem cell transplant, and even surgery (American 
Cancer Society, n.d.).  For more specifics on the chemical makeup of each drug and its function, 
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the reader should consult the Lymphoma Research Foundation and the American Cancer 
Society.   
Physical and Psychological Side Effects of Treatment 
Throughout the treatment of cancer, a patient may experience physical and/or 
psychological effects.  Milanti, Metsälä, and Hannula, (2016) confirmed that psychological 
distress is a common problem among patients with cancer, and that many of these effects are left 
untreated and unreported.  The American Cancer Society (2016) has described physical side 
effects, including heart or nerve damage, as potentially long-term, and has noted that results may 
vary depending upon the individual experience.  Given these findings, more research is needed to 
understand more of the physical and psychological effects a patient may experience.   
Physical.  Cancer patients may experience long-term and/or late effects (Darnley, 
Liebertz, Morales, Vose, & Zebrack, 2009), which vary by the individual patient depending on 
the patient’s treatment, cancer, and biological factors.  Long-term side effects manifest during 
treatment, and may continue for months, and even in some cases up to several years; such effects 
include fatigue, menopausal symptoms, and cardiovascular problems (Darnley et al., 2009).  
While these are only a few of the many side effects experienced long-term, they are significant to 
mention for the purposes of this study in that each may create an emotional struggle for a patient.  
Late effects typically develop post treatment, and may include infertility, osteoporosis, and 
secondary cancers (Darnley et al., 2009).  Late effects in this category may be more noticeable in 
the quality-of-life (QOL) of a patient compared to another who has not undergone treatment.    
Oerlemans et al. (2014) designed a study to determine whether patients suffer from 
anxiety or depression throughout treatment.  Results indicated that younger patients reported 
higher anxiety scores, whereas older patients displayed higher depressive scores (Oerlemans et 
17 
al., 2014).  The results further indicated that 13% of Hodgkin’s lymphoma patients experienced 
anxiety all the time (during treatment) and 11% were always depressed (Oerlemans et al., 2014).  
While these results are specific to Hodgkin’s lymphoma, given the similar treatment protocols, 
these findings likely also apply to NHL.  Further, they indicate that there may be a need for 
patient support from a psychological perspective.   
Psychological.  Existing research has shown that, despite modern progress in securing 
remission, cancer still remains a disease that correlates to feelings of hopelessness, pain, fear, 
and death (R. Singh, H. Singh, C. Singh, & Kaur, 2015).  Singh et al. (2015) described cancer 
diagnosis and treatment as psychologically stressful, resulting from the authentic symptoms of 
the disease and fear that cancer can be a silent killer moving throughout the body without 
warning.  Cancer has retained psychological connotations of grief and pain; research studies have 
indicated that a significant percentage of cancer patients have suffered psychologically (Parker, 
Baile, de Moor, & Cohen, 2003).  Despite the fact that Singh et al. (2015) and Parker et al. 
(2003) suggest that cancer is associated with these negative emotions, there has been a lack of 
research to indicate a connection between the physical effects of treatment and its psychological 
effects.  
Neurobiology: Reaction to Stress and Anxiety 
Research has shown that cancer patients who are being treated with chemotherapy may 
develop distress before treatment (Jacobson, Bovbjerg, & Redd, 1993; Jacobson et al., 1995; 
Sabbioni, Bovbjerg, Jacobson, Manne, & Redd, 1992).  Morrow and Dobkin (1988) have 
theorized these distressed reactions from previous cancer patient’s experiences to classical 
conditioning, or learned responses to the environment and treatment conditions such as physical 
and psychological triggers.  As a patient develops these responses, it may become difficult to 
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disassociate cancer treatment as a distressing situation.  Cameron et al.  (2001) explained how 
the responses to a situation creates ongoing distress for a patient: 
Classical conditioning theory posits that emetogenic cancer treatment (unconditioned 
stimulus [US]) produces a physical side effect of nausea or vomiting (unconditioned 
response [UR]).  Sight, smells, and tastes associated with administration of the therapy 
(conditioned stimuli [CS]) are paired with the toxic treatment, and anticipatory symptoms 
develop (conditioned response [CR]).  Over repeated pairings (treatment cycles) the 
formerly neutral CS alone can elicit the aversive response.  (p. 72) 
 
Given this research, a patient may not be able to avoid these possible triggering conditions 
before, during, or post treatment (Cameron et al., 2001).  The following findings are presented in 
order to enable an understanding of stress and anxiety from a neurobiological perspective, as 
well as how this persistently affects cancer patients.  
Anxiety 
Research has shown that 44% of cancer patients reported a form of anxiety, and 23% of 
cancer patients showed significant anxiety (Schag & Heinrich, 1989; Stark et al., 2002).  With 
these results, there may be a strong need for patients to be assessed throughout the treatment 
process.  Additionally, anxiety results in a predictive response to cancer diagnosis, which occurs 
in varying degrees and may increase as a patient’s disease progresses, or as the treatment 
regimen becomes more aggressive or debilitating (Breitbart, 1995).  Therefore, as the treatment 
regimen progresses, it makes sense that patients’ anxiety levels would increase correspondingly.  
Cancer patients run the risk of developing anxiety disorders that can affect their social roles, 
relationships, and goals relating to life plans (Smith, Cope, Sherner, & Walker, 2014).  This risk 
can increase during cancer treatment when certain factors exist, including: pre-existing condition 
of anxiety disorder, severe pain, present anxiety during diagnosis, limitations with functioning, 
lack in social support, advancing disease, and / or a history with trauma (National Cancer 
Institute, n.d.).  Therefore, a patient’s history pertaining to anxiety should be assessed, and may 
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be helpful for the oncology department to be aware of when treating the patient holistically.  
Patients are often reluctant in speaking to their oncologist about fears and anxieties they may 
have following their diagnosis (Smith et al., 2014).  This may be related to their perception that 
the oncologist is focused only on treating the disease.  Conversely, patients often share emotions 
with nursing staff while engaging in treatment or infusion (Smith et al., 2014).  This may be 
related to the patient’s perception that the oncologist is addressing the body, and the nursing staff 
is more available to check in mentally and physically with the patient throughout treatment. 
Stress 
In a broad sense, stress may be defined as mental responses to demands of the body 
(Koob, 1999).  During a period of stress, the body is signaling the mind that something is 
abnormal.  Therefore, stress is the body’s reaction during a transition requiring a physical, 
mental, or emotional adjustment in response (Selye, 1936).  As the body signals the mind, the 
mind may then identify the mental or physical stressor present.  Stress is known to arise in any 
situation or thought causing frustration, anger, nervousness, or anxiety (Kumar, Rinwa, Kaur, & 
Machawal, 2013).  As an individual’s emotion develops, and if a solution is not found, stress 
may result.   
Stress becomes a stimulus, both internally and externally, that activates the hypothalamic 
pituitary adrenal (HPA) axis as well as the sympathetic nervous system, causing a physical 
change (Maier & Watkins, 1998).  Long-term exposure to stress can result in depression (Nirmal, 
Babu, Harisudhan, & Ramanathan, 2008), post-traumatic stress disorder, and anxiety disorders 
(Kumar et al., 2013).  An individual’s ability to control stress may determine the outcome(s) and 
consequences of that stressor.  Additionally, effects may provoke the development of 
pathological behaviors after a traumatic event (Christianson, Thompson, Watkins, & Maier, 
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2009).  As stress increases, a situation or body signal may escalate or become habitual.  Coping 
with stress becomes a requirement for survival (Kumar et al., 2013).   
The mind/body connection may be a possible factor in producing a positive outcome.  
When the stress becomes problematic, the human brain becomes the target for various stressors 
due to the high sensitivity of stress-induced progressive conditions (Sahin & Gümüşlü, 2007).  
While the brain may be capable of normalizing behavior, it does have limitations when stress is 
introduced.  The brain’s tissue is composed of large amounts of polyunsaturated fatty acid, which 
makes it susceptible to stress attacks (Gutteridge, 1995).  If these attacks continue, a patient may 
experience more dramatic consequences, which may require one’s defense mechanisms to 
commence.  Kumar et al. (2013) discussed stress and dopamine within the following 
neurobiological parameters:   
Stress-induced changes in dopamine (DA) levels within terminal areas seem to involve 
mainly ventral tegmental area projecting cells.  Findings from preclinical studies suggest 
an uneven response of DA in different stressful stimuli.  Specifically, an acute and 
controllable/escapable physical stress was seen to cause and enhanced DA efflux in the 
ventral striatum, whereas chronic and uncontrollable/inescapable exposure to the same 
stress attenuated DA release.  (p. 93) 
 
Brain epinephrine is used as an alarm to the body and decreases neurovegetative functions, 
which contributes to the accompanying increase in autonomic and neurodocrine responses to 
stress (Tsigos & Chrousos, 2002).  Norepinephrine also serves to alert the amygdala, the fear-
related behaviors, and enhance long-term storage of emotional memories in areas such as the 
hippocampus and striatum (Kumar et al., 2013).  Many brain regions are involved in the emotion 
of fear, specifically the limbic system, which regulates emotions and includes the hippocampus, 
amygdala, and prefrontal cortex (Mahan & Ressler, 2012; Myers & Davis, 2007).  Moreover, 
monoaminergic systems aid in regulating the activity of the neurons within the amygdala 
21 
(McGaugh & Roozendaal, 2002).  As the amygdala is less responsive, fear and anxiety are less 
prevalent.  
Psychological and Physical Issues 
Recent advances in research related to mind-body interactions may make it possible to 
evaluate mental experiences in association with physical processes (Lindergren, 2012) which 
could be a helpful resource for research that aims to understand the correlations between physical 
and psychological experiences.  From a psychological perspective, the brain is integral in 
receiving both external sensory input and internal input from the body (Lindergren, 2012).  The 
body acts as the messenger for the brain, and the brain then directs the body as to how to react.  
The brain receives information, which is then integrated with past life experiences, individual 
genetic differences, and various contextual factors (McEwen, 2008; McEwen & Gianaros, 2011).  
Moreover, different individuals may experience the same sensory stimulation differently, as well 
as in different contexts (Lindergren, 2012).  Therefore, it is important to understand the history 
of an individual’s experience in order to more clearly understand their mind-to-body 
connections.  Scholars including Davidson and McEwen (2012) and McEwen & Gianaros (2011) 
have determined that the brain may control and regulate emotion, cognition, behavior, and 
physical responses as the body re-adjusts and balances.  Based on these findings when physical 
touch is implemented, the body sends a signal to the brain that is then affected by past trauma 
and sends a message back to the body as a physical reaction such as tensing or relaxing.  The 
body has the ability to maintain balance, even during physical change, which has a significant 
impact on the mind-to-body interaction (McEwen, 2008).  Limited studies are provided 
regarding the mind-to-body responses during cancer treatment.  Further research is needed to 
clarify whether repeated experiences of treatment could cause the mind and body to react in a 
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resisting response, to which the body may resist certain treatments causing the continuation of 
treatment.  While it would be difficult to conduct a longitudinal study of a cancer patient using 
physical touch in treatment, transitioning to remission, being re-diagnosed, and re-conducting 
treatment to address previous treatment trauma and its effect on later treatment, that research is 
necessary.   
Individuals who are living with cancer are at a higher risk of developing various 
psychological issues (Barre et al., 2015).  A patient may experience psychological difficulties 
beginning with diagnosis, progressing throughout the treatment process, and even remaining 
after treatment.  Research has shown that cancer patients suffer from both physical symptoms 
and psychological symptoms associated with diagnosis and treatment for the disease (Bultz & 
Carlson, 2006).  Additionally, a cancer patient may experience psychological distress at various 
points throughout treatment (Barre et al., 2015).  Extant studies are limited in the sense that, in 
some patients, psychological distress may not be self-recognized (Barre et al., 2015), while 
others may show signs early in treatment, and other patients post-treatment.  The reason for such 
results is unclear; the patient could withhold information or be focused on the conclusion of 
treatment, thereby missing the psychological effects.  It has been determined that patients do not 
always communicate their feelings or may not recognize when they are in distress (Mehnert, 
Lehmann, Cao, & Koch, 2006).  When a cancer patient is diagnosed or engaging in treatment, 
there are certain areas of focus that require attention for the patient.  Research has shown that, in 
addition to and separate from the fear of dying, when cancer patients feel threatened by 
interventions such as chemotherapy and radiation, they are concerned with their bodily integrity, 
independence, and social roles (Faller, Olshausen, & Flentje, 2003).  Patients are vulnerable to 
these various physical and psychological effects and may not be aware of the negative impact 
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treatment creates.  Therefore, future research should focus on both physical and psychological 
aspects for a patient undergoing treatment.  The patient might have more positive results if 
intervention includes both physical and psychological factors, as compared to a purely physical 
treatment process that considers only the remission of the cancer cells.  A patient’s psychological 
health may have more of an impact during treatment than previous research suggests. 
Quality of Life 
A patient’s quality-of-life (QOL) refers to their emotional, social and physical wellbeing, 
and their ability to function in everyday life (Ebbeskog & Ekman, 2001).  A patient may 
experience a drastic change to their daily routine based on their diagnosis and prognosis.  Within 
treatment, much of the focus from the medical staff is on the physical aspects of the cancer-
related outcomes, and less focus accorded to the mental aspects of treatment (Barre et al., 2015).  
The oncology department does have a responsibility to address the patient’s physical disease to 
ensure a positive treatment outcome.  Research conducted by Nayak et al. (2017) expressed that 
the quality of life of cancer patients is of major concern and interventions for patient 
empowerment and a sense of control throughout treatment is desired.  Nandini, Sridhar, 
Usharani, Kumar, and Naveen (2001) created a holistic and comprehensive approach to cancer 
care to enhance QOL at the physical, emotional, social and a spiritual level.  Nandini et al. 
(2001) indicated this approach provided a positive impact within treatment outcomes when 
integrating an approach focused on stress, symptom control, and QOL with the standard 
therapeutic regimens.  Therefore, focusing on both psychological and physical aspects of patient 
care may provide a higher overall treatment outcome in terms of QOL.  Additionally, the 
absence of touch could be linked to the impact of QOL, or the will to live, as evidenced by death 
rates for untouched infants (Hunter & Struve, 1998).  Given the fatality rates of infants in the 
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Hunter and Struve (1998) study, touch may be crucial in moments of physical and psychological 
care across any age.  Given the aforementioned research, physical touch may prove successful as 
an intervention to improve patient QOL.  
Physical Touch 
Development of Physical Touch 
Hippocrates (460-377 BC) discovered that massage was an important medical treatment 
with several different effects: greater amounts of rubbing would thin the body; moderate rubbing 
would thicken the body; hard massage would constrict the tissues; and gentle massage would 
relax the body (Lindergren, 2012).  Therefore, different forms of physical touch could be used 
for different conditions (Calvert, 2002), such as cancer.  More specifically, holding hands as a 
form of physical touch may prove useful in creating the desired effects, such as reduced anxiety, 
within the treatment of cancer patients.   
Touch is one of the most essential elements in in the following areas: human 
development, the insight of communicating, the health and development of infants to adulthood, 
and healing (Bowlby, 1952; Harlow, 1971).  From birth, touch can play an important role in 
one’s life.  Additionally, research has suggested that physical stimulation (touch) is key to 
development and maintenance of both physical and psychological balance from infancy through 
adulthood (Field, 1998; Montagu, 1971).  An infant is cradled in the caregiver’s arms, which can 
create a nurturing bond between the two.  A New York hospital sought to understand the relation 
between mortality and touch.  Findings suggested that when touch was implemented, the rate of 
mortality dropped from 30% to 10% (Cohen, 1987).  This decrease in mortality through the use 
of touch should prompt further studies on the interaction between touch and patients’ mental 
status, as patient improvements were evident (Cohen, 1987).  Moreover, adolescents may seek 
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comfort through the use of touch in moments of insecurity, while adults might seek touch in 
intimate areas of proximity.  Touch is also common in shamanic and religious practices, and 
various healthcare / medical practices (Levitan & Johnson, 1986; Smith, Clance, & Imes, 1998).  
Notably, Harlow (1958) defined touch for its importance in emotional, physical, and 
interpersonal development, as well as making an interesting distinction involving the role of skin 
and physical touch.  The skin can be seen as the most important organ system of the body; unlike 
the other senses of the body, one may not survive without the physical and behavioral processes 
carried out by the skin (Montagu, 1971).  Montagu (1971) also suggested that the longing for 
touch may result in abnormal behavior.  Therefore, skin is paramount for human survival, while 
touch may be essential in the regulation of behavior.  Based on these findings, both touch and the 
skin have a significant role in survival and normalizing behavior. 
Biological development of physical touch.  Describing the biological development of 
touch, Fosshage (2000) addressed the primitive nervous system and the tactile system, both of 
which are central to the early stages of human development.  The primitive nervous system links 
skin cells in our rudimentary brain, and the tactile system is the earliest sensory system in the 
embryo to become functional (Fosshage, 2000).  This early development is crucial, as it precedes 
that of the remaining senses in the body.  Thus, touch is key to development of physical 
tendencies for infants; if development does not occur properly, psychological issues may occur.  
Moreover, studies on bonding suggest that infants with frequent touch in early developmental 
stages show higher results on physical, emotional, and interpersonal scales (Klaus & Kennell, 
1976).  Additionally, research on mother to infant interaction indicates that mutual influence and 
recognition is crucial for early development (Bloch, 2014).  This development may be important 
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from a psychological perspective in reaching a secure attachment, which will be addressed later 
in this study.   
Cultural development of physical touch.  Heller (1997) explained the use of touch is 
diminishing with babies and children.  Heller’s (1997) text credited this finding to the Western 
shift of a Puritan spirit, which teaches parents that by loving your children too much you are 
spoiling them.  Therefore, parents are creating distance from their children, or not even 
hold/touch their children at all (Heller, 1997).  This may account for many psychological issues, 
based on the importance of touch in early development.  Additionally, it seems that social 
pressure and the value for independence or self-sufficiency may have caused American parents 
to distance themselves physically from their children (Mead, 1955).  Despite Heller’s (1997) 
study specific to Western families, D’Agostino’s (2013) results indicate that positive touch may 
be seen as vital for human interaction and the process of bonding.  Further, touch has many 
different meanings for different cultures, depending on socialization and individual experience 
(Halbrook & Duplechin, 1994).  Mead’s (1955) research, then, may suggest that regardless of an 
individual’s cultural background or experience, physical touch is crucial at the early stages of 
development.  The issue seems, at least within the Western culture, to revolve around the 
distorted perception of love and touch and how this impacts children.  To address the distortion 
Tiffany Field has created the Touch Research Institute (TRI).  The TRI informs the community 
the value of physical touch from infancy to senior citizens.  The TRI has conducted over 100 
studies focusing on the various forms of physical touch.   Field’s (2003) research revealed how 
various forms of physical touch are critical for child growth and development and for adult 
overall well-being.  The TRI colleagues are highly cited in more recent studies confirming the 
benefits of touch.    
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Forms of Physical Touch 
Diverse forms of physical touch may be used when working with lymphoma patients.  
There is little to no literature on holding hands as a form of physical touch while treating 
lymphoma patients.  Due to the lack of research on holding hands when treating lymphoma 
patients, research on other forms of physical touch will be used to substantiate the effectiveness 
of touch as used in cancer treatments, including both physical and psychological effects.   
Physical touch and therapeutic touch.  Physical touch is an important proximity 
behavior that reflects both physical and psychological closeness (Andersson et al., 2009).  While 
research may suggest the effect of physical and psychological closeness (Andersson et al., 2009), 
it is important to understand the specifics of these outcomes.  For instance, positive touch is 
indicative of protection, security, and human warmth (Johansson, 2013), which may allow an 
individual to feel psychological effects on an emotional level. In cases involving physical affect, 
skin-to-skin contact becomes a necessary component of nursing care (Carter & Sanderson 1995; 
Edwards 1998; Gleeson & Timmins 2005; Vortherms 1991).  For the purpose of this study, 
related forms of physical touch will be explained to guide understanding of the physical and 
psychological effects created when physical touch is implemented. 
Physical touch is an intrinsic component of nurse-patient interaction in most nursing 
professions (Routasalo, 1999).  Touch is categorized as therapeutic or physical touch.  
Therapeutic touch is focused on a person’s energy field and involves no physical contact, while 
physical touch includes all other types of touch used in nursing, such as hand holding or massage 
therapy (Routasalo, 1999).  When respecting a client’s uniqueness, dignity, wishes, and needs, 
using touch is seen as therapeutic (Goodykoontz, 1979; Hunter & Struve, 1998).  Weber (1990) 
described a distinction between three different touch models: the physical-sensory model, the 
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psychological-humanistic model, and the field model.  In the first model, touch is described as 
contact, while the second form is a way of reaching and communicating (Routasalo, 1999).  The 
third form is a physical act of laying hands on an individual (Routasalo, 1999).  Given these 
distinctions, the types of touch may be interchangeable in various cultural settings as well as 
philosophical situations.  Thus, it is important to apply the correct term in the appropriate setting.  
Observation, questionnaires, bio-physical measurements, and various combined methods can be 
used in conducting research on the effects of touch (Routasalo, 1999). 
Healing touch.  Healing touch is used as a biofield therapy, although the extent to which 
healing touch is helpful for oncology outpatients lacks substantiation (Kemper, Fletcher, 
Hamilton, & McLean, 2009).  This form of physical touch may at times involve physical contact, 
but primarily involves the hovering of hands above an individual.  While the mechanisms for the 
effects of healing touch remain theoretical, case reports and clinical trials propose that it may be 
useful in relieving pain and anxiety (Kemper & Kelly, 2004; Wardell, Rintala, Duan, & Tan, 
2006; Wardell & Weymouth, 2004).  While healing touch has proved useful in several studies, 
research has not yet achieved a valid and reliable outcome as applied to treating cancer patients.   
Intentional comfort touch.  Intentional comfort touch can be applied with the intention 
of changing a patient’s emotions, including holding hands for comfort, as opposed to 
instrumental or procedural touch that has no intended emotional contact (Connor & Howett, 
2009).  The act of holding hands may create an emotional change for the individual going 
through cancer treatment, who often feels anxiety about the process (Connor & Howett, 2009).  
Connor and Howett (2009) provided an approach that can affect a patient’s emotions but does 
not refer to the physical aspects a patient may experience.  Thus, it is necessary to address this 
29 
type of touch in future studies to measure the effects of anxiety, both physically and 
psychologically.   
Holding hands.  Hand holding as an intervention to manage anxiety has not been limited 
to the population of cancer patients undergoing treatment.  Pirbudak and Tepe (2017) introduced 
hand holding in the context of gynecology procedures at the single case level, and all participants 
displayed positive effects in terms of pain and anxiety.  Similarly, Ergott (2008) described a 
birthing experience in which vital signs were alarmingly low raising concern.  Despite the efforts 
of the medical staff, Ergott (2008) believes it was the strength drawn from hand holding of the 
nursing staff that kept the mother alive throughout delivery.  Based on the aforementioned 
research, the non-invasive intervention of holding hands during medical treatment appears to 
create positive effects for patients.  Post diagnosis, the psychological side effects of non-
Hodgkin’s lymphoma can affect patients’ overall wellbeing, future outlook, and relationships 
with others (Adler & Page, 2008).  
Holding hands has a soothing effect, reduces anxiety, and provides the two engaging in 
the form of physical touch a feeling of increased security (Rubin, 1963).  Rubin (1963) has 
addressed the effects of hand holding on anxiety in patients having cataracts surgery; the results 
indicated that patients engaged in hand holding experienced lower levels of anxiety than those of 
the control group, and that epinephrine levels were significantly lower as compared to the control 
group.  Another study by Moon and Cho (2001) suggested that hand holding can be applied to 
relieve anxiety.  Despite the lack of research specific to hand holding, the Moon and Cho (2001) 
study suggests the benefit of hand holding, and that it should be applied in further medical 
studies.   
Maresh et al. (2013) measured both state and trait anxiety; their research indicates that 
30 
the role of social support through holding hands regulates emotional responses in anxious 
individuals.  State anxiety is described as an unpleasant emotional stimulation in threatening 
demands or dangers (Schwarzer, 1997).  Lazarus (1991) explains a threat must be experienced 
for the mind to appraise this emotion.  Trait anxiety, however, reflects the presence of 
established individual variances in response with state anxiety in the expectation of threatening 
situations (Schwarzer, 1997).  Additionally, Oh and Park (2004) found that both hand massage 
and hand holding are effective nursing interventions contributing to psychological and 
physiological anxiety alleviation for patients undergoing local infiltration anesthesia.  Similarly, 
a phenomenological study of cancer patients undergoing treatment revealed that hand holding 
was a distraction from treatment, a source of security, and reduced pain through patients feeling 
more secure (Weekes, Kagan, James, & Seboni, 1993).  Therefore, active engagement through 
holding hands with an individual with whom they are securely attached daily may prove useful 
for both patients and caregivers in managing the effects of anxiety for cancer patients.   
Massage touch.  The use of massage touch could produce physical, emotional, cognitive, 
and social effects (Gallace & Spence, 2010; Hertenstein, Holmes, McCullough, & Keltner, 2009; 
Loken, Wessberg, Morrison, McGlone, & Olausson, 2009; McCabe, Rolls, Bilderbeck, & 
McGlone, 2008; McGlone, Vallbo, Olausson, Loken, & Wessberg, 2007; Morrison, Loken, & 
Olausson, 2010; Olausson, Wessberg, Morrison, McGlone, & Vallbo, 2010; Rolls, 2010).  An 
individual may experience one or more of these effects through this form of physical touch.  
Kunter et al. (2008) found that massage touch provided a way to interrupt emotional distress, and 
other factors such as a relaxation response and blood circulation.  Despite these findings, the 
research explained the difficulty of creating randomized trials, and that, consequently, few 
studies have assessed the efficacy of massage touch (Kunter et al., 2008).   
31 
Research on Forms of Physical Touch 
Research on different forms of physical touch will be outlined for more understanding of 
the physical and psychological effects produced during the treatment of lymphoma patients.  
Generally, research on touch has focused on three main aspects: the use of physical touch, the 
effects of physical touch, and a patient’s experiences with physical touch.  Research conducted 
by Routasalo (1999) indicates that the results varied, but consistency was shown in that touch 
generally had a comforting and calming effect.  Thus, the use of touch massage may be 
therapeutic and purposefully used as comforting (Lindgren, 2012).  Holding hands may also 
prove useful in creating a comforting and calming effect for a lymphoma patient, though 
research is currently lacking in this area.   
Early research on physical touch.  Throughout time, touch has been suggested as 
essential for reproduction and survival (Grabenhorst & Rolls, 2011).  More directly, touch can be 
seen as a necessity for humans.  Additionally, the importance of touch may begin during infancy.  
Many have noticed how forms of touch influence weight, cognition, stress tolerance, and gene 
expression among newborns (Claessens et al., 2010; Dunbar, 2008; Field, 2002; Field, Diego, & 
Hernandez-Reif, 2010; Liu, Diorio, Day, Francis, & Meaney, 2000; Weaver et al., 2005).  As 
influential as touch is among newborns, one might suspect the role of touch throughout life to be 
correlated to overall health.  Lindergren (2012) clarified this point by explaining that touch is 
important from both evolutionary and developmental perspectives, as well as in healthcare.  This 
may signify the importance of touch in both physical and psychological aspects for humans.  
Additionally, Connor and Hewitt (2009) contended that touch is important for both healthcare 
professionals and their patients.  However, it is also important to identify specific areas touch can 
be used for within healthcare.  Ruffin (2011) explained that touch has been used to treat stress, 
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insomnia, exhaustion, and constipation effectively since the late 1800s.  While research has 
developed more specifically since the 1800s, results remain limited in terms of comparative 
studies.   
 Responses to physical touch.  From a qualitative stance, there have been many positive 
findings related to implementing physical touch into an individual’s treatment.  More 
specifically, physical touch has shown to decrease negative emotions such as anxiety, pain, 
stress, loneliness, and meaninglessness, and to reduce psychological symptoms across a wide 
variety of patients and symptoms (Andersson, Tornkvist, & Wandell, 2009; Beider & Moyer, 
2007; Billhult, Lindholm, Gunnarsson, & Stener-Victorin, 2008; Billhult & Maatta, 2009; 
Cronfalk, Ternestedt, & Strang, 2010; Diego, Field, Sanders, & Hernandez-Reif, 2004; 
Falkensteiner, Mantovan, Muller, & Them, 2011; Henricson, Ersson, Maatta, Segesten, & 
Berglund, 2008; Kim & Buschmann, 1999; Lamas, 2011; Lamas, Graneheim, & Jacobsson, 
2012; Suzuki et al., 2010).  A majority of extant research resulted in similar conclusions in that 
physical touch creates positive psychological outcomes for an individual.  However, each of the 
aforementioned studies designed to reduce psychological symptoms concluded that further 
research is necessary to investigate further patients and symptoms.   
Observed responses during and after massage touch have contributed to various theories 
of the effects of physical touch (Moyer, Rounds, & Hannum, 2004).  One theory in particular 
claimed that the hormone oxytocin (also known as the bonding chemical), is released during 
touch or massage, and that the release of oxytocin may explain positive responses (Uvnas-
Moberg, 1998).  However, several studies have failed to support oxytocin as a bonding agent 
with regard to physical touch (Billhult, Lindholm, Gunnarsson, & Stener-Victorin, 2008; 
Henricson, Berglund, Maatta, Ekman, & Segesten, 2008; Wikstrom, Gunnarsson, & Nordin, 
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2003), limiting the efficacy of findings regarding this effect.  Oxytocin’s utility as an anti-stress 
marker has been doubted, due to the fact that stressful events increase the level of oxytocin 
produced (Semeniken, Merchenthaler, Hu, & Dudas, 2009).  Thus, as anxiety increases, so does 
the release of oxytocin.  Based on aforementioned research and conclusions, one may assume 
that, during anxiety, physical touch triggers the release of oxytocin as a way to de-escalate 
anxiety; however, research is limited.   
Results of implementing physical touch as an intervention within the sections 
aforementioned quantitative research presented similar results to qualitative research, with few 
divergences.  For instance, research has shown that massage touch may lower systolic blood 
pressure and heart rate for breast cancer patients (Billhult, Lindholm, Gunnarsson, & Stener-
Victorin, 2009).  However, more research is necessary due to conflicting results; studies should 
be conducted with larger sample sizes, and specifically designed so that stress can be measured 
both before and after treatments (Moraska, Pollini, Boulanger, Brooks, & Teitlebaum, 2010).  
Research has shown positive outcomes, but only with limited participants, which can weaken 
validity and reliability.  With more measured outcomes, the results may produce different results 
than previous conflicting results.  Responses to physical touch can be seen as beneficial in extant 
research; however, implementing physical touch in specific cases may show further results as to 
its effectiveness.   
Physical Touch and Cancer Treatment 
Previous research on physical touch in different types of cancer settings provides support 
for this study.  Wardell and Weymouth (2004), conducted a review of existing studies, and 
concluded that touch results in reduced anxiety and pain, accelerated healing, some improvement 
in biochemical and physical markers, and an overall improved sense of wellbeing.  Wardell and 
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Wymouth (2004) suggested that anxiety, stress, and accelerated healing are present during a 
cancer treatment regimen.  Pain associated with advanced cancer has been known to cause 
physical and emotional distress, which can lead to decreased functional ability and quality-of-life 
(Kunter et al., 2008).  In the study designed by Kunter et al. (2008), 380 patients with advanced 
cancer showed improvement in pain and mood immediately after a treatment when using a 
massage therapist, while the use of touch alone resulted in less improvement.  Weekes, Kagan, 
James, and Seboni (1993) conducted a phenomenological study in which all 20 participants 
perceived hand holding to be an effective coping strategy in relieving treatment-related pain.  
More importantly, the participants preferred to hold the hand of their mother, although each 
would hold the hand of a nurse in the absence of their mother (Weekes et al., 1993).  Lastly, the 
intervention of hand holding assisted the subjective experiences of the participants in feeling 
more secure, less tense, and provided a distraction from treatment (Weekes et al., 1993).  The use 
of physical touch specific to hand holding in cancer treatment has proved beneficial and has 
provided evidence that who the participant holds hands with is equally important.     
Relationship Attachment 
John Bowlby (1969) conceptualized attachment theory as a model for social and 
developmental implications beginning from the stages of childhood and infancy.  Attachment 
theory hypothesizes that an attachment system will evolve in order to maintain proximity 
between an infant and its caregiver when threatened (Bartholomew & Horowitz, 1991).  Thus, 
the quality of an early attachment relationship is rooted in the degree to which an infant has 
become reliant on its attachment figure for security (Ainsworth, Blehar, Waters, & Wall, 1978).  
Additionally, attachment theory has suggested that humans have a tendency to make strong, 
affectionate bonds to significant others throughout their lives (Bowlby, 1977).  The term 
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relationship attachment may be used to define these relationships.  There are three distinct 
patterns of attachment: secure, anxious, and avoidant (Ainsworth et al., 1978).  An individual 
within a secure attachment may find flexibility within the relationship.  Those in an anxious-
resistant relationship could be overly involved or scattered in the realm of emotions, while those 
who are avoidant may tend to avoid areas of conflict or even intimacy.  Within relationship 
attachment, anxious and avoidant patterns could be seen indicators of stress and anxiety within a 
relationship, while a secure relationship attachment may indicate lower levels of stress and 
anxiety (Ainsworth et al., 1978; Bowlby, 1977).   
Neurobiology with Relationship Attachment.   
Within psychosocial oncology, the term adjustment is used to define the cognitive and 
behavioral mechanisms people use when faced with the threat to wellbeing affiliated with cancer 
diagnosis and treatment (Brennan, 2001).  In many cases a patient may not know how to adjust 
emotionally to the diagnosis.  In a psychological framework, adjustment relates to the emotional, 
social, and physical challenges that arise during psychological symptoms and quality-of-life 
disruptions (Nicholls et al., 2014).  As these disruptions occur, an individual may adapt and 
progress or remain in the present adjustment.  Moreover, psychological distress will not always 
lead to a diagnosable illness, but psychosocial factors can affect patients’ treatment outcomes, 
disease progression, and survival rates (Soler-Vila, Kasl, & Jones, 2003).  While the research 
conducted by Soler-Vila, Kasl, and Jones (2003) is informative, it does not offer a clear 
interpretation on the statistical effects of physical distress.  Therefore, further research is needed 
to better understand how and if levels of distress can affect treatment outcomes through 
comparative randomized studies with cancer patients.   
Johnson et al. (2013) conducted a comparative study using functional magnetic resonance 
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imaging (fMRI) to scan a patient’s brain activity during a threat and determine how secure 
attachment may impact reactions in the following situations: patient left alone while having his 
or her ankles shocked; when a stranger was present holding the patient’s hand while the patient’s 
ankles were shocked; and when the partner of the patient was holding the patient’s hand while 
the patients ankles were shocked.  Results from the fMRI showed more threat-related activity 
from the patient when alone than when a stranger was present holding the hand of the patient 
(Johnson et al., 2013).  Moreover, the comparison between a stranger and the patient’s partner 
resulted in a greater threat of brain activity with a stranger present while holding hands and the 
patient’s ankles being shocked (Johnson et al., 2013).  When a patient is holding hands with an 
individual with whom they experience a secure attachment, their brain’s threat detection may be 
lower than when shocks are administered when they are alone or with a stranger with whom they 
do not have a secure attachment.   
Relationship Attachment Styles 
Anxious and avoidant attachment styles.  During the adjustment process in treatment, 
it is common for a patient to seek a relational attachment from another individual, during which 
maladaptive behaviors can occur (Nicholls, Hulbert-Williams, & Bramwell, 2014).  Maladaptive 
behaviors consist of avoidant attachment behaviors and anxious attachment behaviors (Nicholls 
et al., 2014).  When a threat is perceived, an avoidant attachment individual may seek close 
proximity with others, while the anxiously attached individual may withdraw and seek more 
independence.  Both attachment styles may be classified as insecure attachment.  Insecurely 
attached patients could have poorer results in terms of their psychological adjustment to cancer 
(Nicholls et al., 2014).  In addition, studies have shown that insecurely attached caregivers may 
experience depression, stress, and less motivation towards caregiving (Nicholls et al., 2014).  
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When both patients and caregivers are experiencing an insecure attachment behavior, the 
outcome may be harmful as both resist connection leading to a secure attachment relationship.   
Secure attachment.  In contrast to the negative effects of anxious and avoidant 
attachment styles, secure attachment has shown to contribute to positive growth and better 
wellbeing (Nicholls et al., 2014).  Secure attachment may produce positive effects in terms of a 
patient’s relationship attachment as well as for the use of positive growth emotionally and better 
wellbeing (Nicholls et al., 2014).  While this attachment style may be used in many therapeutic 
settings, limited research has addressed secure attachment in relation to a cancer treatment 
setting.   
Summary of Review of Related Literature 
 In relation to the relevant literature on physical touch, anxiety, relationship attachment, 
and non-Hodgkin’s lymphoma, two themes are most significant for the purposes this study.  
First, although holding hands is a form of physical touch, there is a lack of research measuring 
the effects created.  Second, there is a gap in research that addresses the relationship between 
cancer patients holding hands to reduce anxiety, while administered by an individual with whom 
the patient is securely attached.  While different forms of physical touch have been implemented 
into cancer treatment, extant studies have not taken into account the level of relationship 
attachment between the participants.  The following three chapters present a new intervention for 
cancer patients being treated for non-Hodgkin’s lymphoma, addressing daily psychological 
anxiety during treatment through holding hands with a secure attachment during each treatment.   
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CHAPTER III:  
METHODOLOGY 
Chapter three will consist of the following topics: research questions and hypotheses, 
research design, participants, instruments, procedures, analysis of data, and summary. 1   
Research Questions and Hypothesis 
Research Question One  
Does hand holding with a secure attachment decrease the state and trait anxiety of non-
Hodgkin’s lymphoma patients during treatment, as measured by the STAI (Speilberger et al., 
1983)?   
Hypothesis one. Participants utilizing hand holding with a secure attachment during 
treatment will display decreasing trends in both state and trait anxiety, as measured by the STAI 
(Speilberger et al., 1983). 
Research Question Two 
Does hand holding with a secure attachment during treatment decrease the state anxiety 
of non-Hodgkin’s lymphoma patients more compared to only having the secure attachment 
present during treatment, as measured by the STAI (Speilberger et al., 1983)? 
 Hypothesis two. Participants utilizing hand holding with a secure attachment will 
demonstrate lower levels of anxiety during treatment than when not hand holding in the presence 
of a secure attachment, as measured by the STAI (Speilberger et al., 1983). 
Research Question Three 
Does hand holding with a secure attachment during treatment decrease the state anxiety 
of non-Hodgkin’s lymphoma patients below the cutoff score of 39, as measured by the STAI 
(Speilberger et al., 1983)?                                                         
1 Henceforth within the methodology, the terms patients and participants will be used interchangeably.   
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 Hypothesis three.  Participants utilizing hand holding with a secure attachment during 
treatment will display significant scores below the cutoff of 39 for state anxiety, as measured by 
the STAI (Speilberger et al., 1983). 
Research Design 
The focus of this study was comparing the effectiveness of hand holding with a secure 
attachment during non-Hodgkin’s lymphoma treatment in relation to patients’ state and trait 
anxiety levels.  The researcher took recognition in that the recorded data points available were 
minimal; and thus assessed participants one through three using various single-case designs to 
strengthen the validity of the hand holding intervention.  The phases utilized in these single case 
studies were priori, given the short amount of measures available; thus, only six chemotherapy 
measures and one CT scan meeting were completed.  The CT scan meeting consists of the 
participants meeting with their oncologist to review the results and prognosis of their CT scan 
and future treatment regimen(s).  Participant one underwent a monitoring B-design to evaluate 
the effects of hand holding during treatment.  As the results were evaluated, it proved necessary 
to see how other participants would react to the intervention.  Thus, the researcher used a B-A 
design for participant two and an A-B design for participant three.  In total, three participants 
participated in the study to its completion.   
According to Ray (2015), when using an A-B design, A (Phase A) refers to the baseline 
stage and B (Phase B) signifies the intervention stage.  For the purposes of this study, during 
Phase A, the participant did not receive the hand holding intervention; within Phase B, the 
participant received the intervention of hand holding with the secure attachment.  Within Phase 
A, if the data points show a stable trend of increasing or higher scores of anxiety, then Phase B 
would need to show lower scores to indicate significance.  Since Phase A does not utilize the 
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intervention of hand holding with a secure attachment and Phase B does, this is why the trend 
direction has been decided as such.  While the study has limited time points, there may be a lack 
in stable baseline for each participant.  However, participants served as an autonomous control 
(Ray, 2015) for their respective measures, since their scores are independent of the population 
scores.  Further, participants one and two were both measured under the same time frame except 
for the CT scan meeting.  Participant three was measured under a different time frame given the 
different diagnosis.  Engel and Schutt (2013) suggested that researchers must be able to measure 
a participant’s status at regular time intervals, such as hours, days, weeks, or months.  Finally, 
following the Secure Attachment Protocol Form (Appendix E), the researcher took STAI 
measures (Speilberger et al., 1983) 30 minutes after the start of treatment and after the CT scan 
meeting.   
B-Design: Participant One 
The researcher used a B-design, which only has an intervention phase, for participant 
one.  This design was used to determine how the participant progressed (Engel & Schutt, 2013) 
and to monitor the anxiety levels of participants across treatment and at the CT scan meeting.  
However, Engel and Schutt (2013) have explained that the actual improvement cannot be 
attributed to the intervention, as there may be threats to internal validity.  Therefore, the 
researcher chose participant one to help identify any threats to internal validity, and provided a 
form of monitoring for the impact of particular interventions (Engel & Schutt, 2013), which 
would be compared to other participants time points.  Specifically, if the researcher had used a 
standard A-B single-case design, it would be possible to argue that the effectiveness in reducing 
patient anxiety was not only due to hand holding, but perhaps due only to the presence of a 
secure attachment.  Thus, the researcher used a B-design with participant one with the 
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intervention of hand holding with a secure attachment to help identify a target range of anxiety 
scores for the other participants.  Again, no statistical significance can be drawn from a B-design, 
as a baseline measure is absent (Engel & Schutt, 2013).  However the data collected offered 
valuable information and direction in how to proceed with participants two and three.  The 
researcher tracked participant one’s anxiety throughout five chemotherapy measures holding 
hands to create a trend, then the researcher measured the CT scan meeting, and concluded with 
one final chemotherapy measure.  The last chemotherapy measure was used to see if the CT scan 
meeting affected the participant’s anxiety.  This could be argued as a threat to internal validity, 
and raises the need for more participants using a different single-case design.  Thus, the 
researcher used a B-A design on the next participant.   
B-A Design: Participant Two  
The researcher selected a B-A design to study the effectiveness of hand holding on 
participant two.  A B-A design is used as a reversal from intervention to baseline, where the 
intervention is hand holding and the baseline is the absence of hand holding with the secure 
attachment present for treatment.  As participant one had undergone a B-design, the researcher 
sought to further the understanding of hand holding on participant two.  In the B-A design, the 
participant’s first measure was the CT scan meeting, followed by six chemotherapy measures.  
The CT scan meeting and the first three chemotherapy measures were undertaken in the presence 
of the intervention of hand holding with a secure attachment.  Then the participant was placed 
into the baseline phase for the last three chemotherapy measures; the secure attachment was 
present, but hand holding did not occur.  The participant agreed that the intervention of hand 
holding was beneficial and would be used going forward.  While this design allows for 
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comparison between phases, it was still crucial to complete an A-B design on participant three 
under the same conditions as those used for participant two, regarding the CT scan meeting.  
A-B Design: Participant Three 
 The researcher chose to study the effectiveness of hand holding on participant three using 
an A-B design, where the baseline of a secure attachment’s presence is first measured, then 
followed by the intervention of hand holding.  Thus, participant three went through the CT scan 
meeting and the first three chemotherapy measures without holding hands, and then completed 
the three remaining chemotherapy measures holding hands.  In both designs used for participants 
two and three, the use of repeated baseline measurements allowed the researcher to reduce 
threats to internal validity (Engel & Schutt, 2013; Ray, 2015).  In either reversal design, due to 
the time-sensitive nature of the chemotherapy treatments, it was necessary to restrict the baseline 
phase to three sessions. 
Procedural Changes 
 A procedural change arose in this dissertation when participant one had to move the CT 
scan meeting.  The participant’s primary oncologist determines when a CT scan will occur, and 
the researcher desired for participant one to have the CT scan meeting between the first and last 
three chemotherapy measures to provide at least three measures on the baseline and intervention 
phases.  With the adjustment to participant one’s CT scan meeting occurring after the fifth and 
before the sixth chemotherapy session, this caused an adjustment in selecting candidates for the 
two remaining designs.  Thus, the researcher sought to control for this varying variable in future 
participants, as the results of the CT scan meeting could have an effect on the anxiety of 
participants.  The researcher also wanted to have the CT scan meetings for participants two and 
three to occur between chemotherapy measures three and four.  Since this was out of the control 
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of the researcher, it was easier to control time point chemotherapy measures if the CT scan 
meetings were moved to the initial measure for participants two and three.  Lastly, the researcher 
desired another participant to undergo a B-design, where the participant would not hold hands 
with a secure attachment, but go through the CT scan meeting and the six chemotherapy 
measures just with a secure attachment present.  However, this participant withdrew from the 
study.  The Post Session Questionnaire (Appendix F), which is addressed in the next section, 
helped determine any variations from protocol.  As data was collected after each measure, the 
researcher could make accommodations as needed.  
Instruments 
Participant Screening Form  
 The researcher used the Participant Screening Form (Appendix D) to clarify the 
following: that the patient has non-Hodgkin’s lymphoma in stages one-four; if a secure 
attachment is accessible by an individual, and to select a secure attachment who can be present at 
each treatment administered.  Both the non-Hodgkin’s lymphoma patient and designated secure 
attachment completed this form.  Secure attachment, as defined in this study, is the enduring 
emotional bond a person feels with another that results in the ability to manage anxiety.  The 
selected person is identified throughout the study as secure attachment.  Refer to Appendix A for 
more details.   
Secure Attachment Protocol Form  
 The researcher provided the Secure Attachment Protocol Form (Appendix E) to the non-
Hodgkin’s lymphoma patient’s secure attachment.  The protocol form consists of duties to 
perform throughout the study.  The researcher required the secure attachment to arrive for each 
session of chemotherapy, record responses directly from the non-Hodgkin’s lymphoma 
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participant on the STAI (Speilberger et al., 1983) not influence or challenge responses, and hold 
hands with the non-Hodgkin’s lymphoma participant during the intervention phase designated.  
Lastly, the secure attachment was required to complete the Post Session Questionnaire 
(Appendix F) after each measure, and return all documents to the researcher.  Refer to Appendix 
B for more details. 
Post Session Questionnaire 
 Secure attachments completed he Post Session Questionnaire (Appendix F) after the 
completion of the STAI (Speilberger et al., 1983).  The questionnaire is designed to allow the 
secure attachment to explain the following: any deviation from the Secure Attachment Protocol 
Form (Appendix E), any external influence that may impact the STAI (Speilberger et al., 1983) 
results, and any personal reflection on the part of the non-Hodgkin’s lymphoma participant or the 
secure attachment.  The questionnaires were returned to the researcher.  Refer to Appendix C for 
more details.   
State-Trait Anxiety Inventory  
The researcher selected the State-Trait Anxiety Inventory (STAI; Speilberger et al., 1983) 
for this study for the purpose of distinguishing distress over time and how scores can change 
given support systems, overall health, and individual factors (Elliott, Shewchuk, & Richards, 
2001; Shewchuk, Richards, & Elliott, 1998).  The researcher purchased appropriate licenses to 
use the STAI (Speilberger et al., 1983) from Mind Garden.  The purpose of this study was to 
measure anxiety over time as well as each participant’s active anxiety during treatment.  
Therefore, the STAI (Speilberger et al., 1983) was useful in assessing state and trait anxiety 
(Speilberger et al., 1983).  Form Y is a version of the STAI that may be used in clinical settings 
to diagnose and differentiate anxiety symptoms from depressive symptoms (Speilberger et al., 
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1983).  Further, Form Y is unique in that it differentiates state and trait anxiety within one 
assessment (Speilberger et al., 1983).  Form Y consists of 40 total questions, and requires a sixth-
grade reading level (Speilberger et al., 1983).  Twenty of the questions pertain to state anxiety, to 
assess present anxiety symptoms, while the remaining twenty questions address trait anxiety, 
which is related to more personal traits.  Each item is rated on a four-point Likert scale ranging 
from almost never, scored as one, to almost always, scored as four.  Scores range from 20 to 80, 
with higher scores correlated with greater anxiety (Speilberger et al., 1983).  Speilberger et al. 
(1983) reported internal consistency coefficients ranging from .86 to .95.  Across a two-month 
interval, the test-retest reliability coefficients varied from .65 to .75.  Lastly, Julian (2011) 
suggested a cutoff score of 39-40 is recommended to demonstrate clinical significance for state 
anxiety.  Thus, the researcher determined participant scores exceeding 39 demonstrate more 
clinical anxiety at the state level and scores at 39 or below demonstrate the effectiveness of the 
intervention to reduce state anxiety clinical significance.  
Participants 
 The study desired to have a criterion-based sample of up to ten participants with non-
Hodgkin’s lymphoma, classified within stages one-four, at an oncology site in the mid-south.  
However, only three participants were selected out of the recruitment and screening process.  
While there are numerous sub-categories of non-Hodgkin’s lymphoma, any participant 
diagnosed under this category was eligible for admittance to this study.  Upon the patient’s 
diagnosis, their primary oncologist asked the patient whether they would like to participate in the 
study.  The researcher was in contact with a lead oncologist who treats lymphoma of all kinds, 
and provided the oncologist with contact information (phone number and e-mail address), and 
research description (i.e., consent), for dissemination upon approval by the patient.  When a 
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patient agreed to participate in the study voluntarily, the researcher contacted the patient and 
provided all necessary information.  This initial contact also enabled the researcher to determine 
whether the patient was eligible to participate in the study.  Participants were required to meet 
the following criteria: (1) be diagnosed with non-Hodgkin’s lymphoma between stages one and 
four; (2) be 18 years of age or older, and speak / read English; (3) not be diagnosed with a 
previous lymphoma cancerous disease; (4) must be medically stable if mental health diagnosis 
present; (5) if a mental health diagnosis is present, stability is defined by regulatory psychotropic 
drugs prescribed by a primary oncologist and/or general physician; (6) have a secure attachment 
that who attend and make STAI (Speilberger et al., 1983) recordings; (7) and demonstrate 
clinical suitability for participation via the Participant Screening Form (Appendix D).  Patients 
were informed that they could drop out of the study with no penalty or hindrance to their 
treatment regimen at any point.  
 In addition to the non-Hodgkin’s lymphoma patient, the patient’s secure attachments 
were asked to participate in the study.  To become eligible for admittance into the study, the 
secure attachment was required to meet the following criteria: (1) attend each treatment with the 
non-Hodgkin’s lymphoma patient; (2) be 18 years of age or older, and speak / read English; (3) 
be able to hold the hand of the non-Hodgkin’s lymphoma patient; (3) be physically able to record 
responses given by the non-Hodgkin’s lymphoma patient; (4) and be willing / able to adhere to 
the Secure Attachment Protocol Form (Appendix E).  The secure attachment could drop out of 
the study at any time with no penalty or hindrance to the self or the treatment process of the non-
Hodgkin’s lymphoma patient.   
 To find suitable candidates to participate in the study, the researcher was trained in the 
technology portal used by the oncology staff.  In using this portal, the researcher had access to 
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information including patient medical records, notes, and treatment regimens as a pre-screening 
method.  Each week, the researcher would arrive at the oncology setting and run a patient visit 
report for the following week.  Once the report was complete, the researcher would scroll 
through each list of scheduled patients to find those diagnosed with non-Hodgkin’s lymphoma.  
After finding the non-Hodgkin’s lymphoma patients, the researcher created an Excel file to track 
each patient by their medical number (MRN).  The researcher then gave a list of potential 
candidates’ MRNs to a nurse on staff, who assisted the researcher with interpreting patients’ 
diagnosis and treatment regimens, as this was not in the researcher’s scope of practice.  Once the 
researcher reviewed the list of potential candidates, the researcher would provide the appropriate 
oncologist with the patient MRNs to indicate research interest.  The oncologist would determine 
whether the patient would be approved for candidacy before asking the patient to join the study.  
Once the oncologist received approval from a patient, the screening process continued with the 
researcher contacting the patient and discussing research interest.  If the patient was interested, 
the researcher emailed the informed consent (Appendix C) and aforementioned documentation to 
the patient.  Once the patient received all documents, the researcher contacted the participant to 
review each document over the phone.   
The patient would then sign and hand deliver the informed consent (Appendix C) to the 
nursing staff for records keeping upon arrival of the first measure where all measurement 
materials were awaiting in their folder.  The researcher created a participant folder, which 
consisted of enough STAI (Speilberger et al., 1983) forms and Post Session Questionnaires 
(Appendix F) for the participants to record for any remaining measures.  Folders were given to 
the participants by the nursing staff for completion and returned to the nursing staff after each 
treatment.  Folders were kept with the oncology research team, who are affiliated with the Mid-
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South oncology center, in a secure location on-site until the researcher could arrive for collection 
of records.  Once a participant completed all requirements, they received a gift card.  The gift 
card was a 25-dollar gift card to the location/service of choice to the participant.  Again, while 
the researcher desired 10 participants for the study, 19 possible participants were asked to join 
throughout the study.  Out of the 19 potential participants, 12 declined to be included into the 
study.  Within the remaining seven potential participants, all approved to be involved in the 
study.  However, before measures could begin, four participants dropped out.  Two of the four 
participants had to be removed from the study due to a diagnosis change (a more threatening 
cancerous disease needed to be treated before the non-Hodgkin’s lymphoma).  The third 
participant had completed the CT scan meeting and started chemotherapy measures before 
deciding to withdraw from the study due to complications with the secure attachment being 
present.  The fourth participant received news that there was no evidence of diseases and thus 
was removed from the study.  Therefore, only three (N = 3) participants completed the study with 
the CT scan meeting and six chemotherapy measures.   
Participant One  
Participant two is a 61-year-old male who was diagnosed with stage three diffuse B-cell 
non-Hodgkin’s lymphoma.  Information provided on the Participant Screening Form (Appendix 
D) indicated that the participant was married, Caucasian and Hispanic, and had no mental 
disorder diagnosis at the time of the study.  During interview, the participant seemed eager to 
begin the study and wanted to give back to the field of cancer research.  Further, this participant 
considered himself very active in his daily life, consisting of sports, business, and family time.  
The participant selected his wife as the secure attachment individual who would attend each time 
point measure.  The secure attachment individual was fully committed to the study and 
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responsibility that followed.  Lastly, the participant’s time points were recorded by the secure 
attachment at both the Mid-South oncology setting (North campus) and the hospital setting.   
Participant Two 
Participant two is a 70-year-old female who was diagnosed with stage two diffuse B-cell 
non-Hodgkin’s lymphoma.  The Participant Screening Form (Appendix D) revealed that the 
participant was married, Caucasian / Non-Hispanic, and was given Duloxetine (30 mg) for 
diagnosed anxiety regularly.  During the initial interview, the participant indicated that she was 
happy to assist in research and was in favor of the idea of hand holding during treatment.  The 
participant expressed that she valued family closeness and support.  The participant selected her 
husband as the secure attachment individual who would attend each time point measure.  The 
secure attachment was fully committed to the study and responsibility that followed.  Finally, the 
participant completed the CT scan meeting and treatments at both the Mid-South oncology 
setting (North campus) and hospital.  
Participant Three 
Participant three is a 71-year-old male who was diagnosed with unstagable (due to 
limited pathology) B-cell follicular non-Hodgkin’s lymphoma.  It is important to note the 
researcher conferred with the lead oncologist and it was determined the participant would be 
treated for stage three, and thus included.  Information on the Participant Screening Form 
(Appendix D) revealed that the participant was married, Caucasian / Non-Hispanic, and was 
taking Prozac to manage his diagnosed post-traumatic stress disorder (PTSD).  During the 
interview process, the participant expressed that he was a calm person who did not experience 
much anxiety in life.  Nevertheless, the participant was willing to aid in research and selected his 
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wife as the secure attachment individual who would attend each time point measure.  Finally, the 
participant competed all measures at the Mid-South oncology setting (South campus).  
Context 
Setting 
 All participants received treatment and completed the CT scan meeting at either a Mid-
South oncology setting or the affiliated hospital nearby.  This oncology department had two 
locations each approximately 30 minutes apart, and hospitals minutes away from their North and 
South locations.  Depending on where the participant lived, the North or South campus was used 
for treatment.  Participant one and two each received two chemotherapy treatments at the North 
location and had a private room in which to receive treatment.  Participant three received 
treatment in a private room at the South location.  All CT scan meetings were conducted in a 
normal patient meeting room.  Participants would arrive to the oncology setting and check in for 
their appointment.  In future studies, researchers should become familiar with protocol of patient 
care at the selected setting.  This will assist in tracking participants as they transition from one 
appointment to another.   
Procedures 
Informed Consent 
 The researcher received approval from the Institutional Review Board (IRB) of the 
University of Arkansas to conduct this study (Appendix A).  Further, IRB approval was obtained 
from the local oncology department to screen and study the patients treated there (Appendix B).  
Upon acceptance into the study, the cancer patient and secure attachment were required to 
provide written informed consent (Appendix C) and complete the Participant Screening Form 
(Appendix D).  Participants were informed that they may drop out of the study with no penalty or 
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hindrance to their already established treatment at any point.  Finally, they were informed that 
inclusion in the study would not guarantee positive or negative results of their cancer treatment 
or psychological wellbeing, and that to abstain from participation would in no way impact their 
scheduled treatment regimen as prescribed by their oncologist. 
Sampling Procedures 
Cancer patients.  Initially, each non-Hodgkin’s lymphoma patient being treated with 
chemotherapy met with their primary oncologist to explore the possibility of participating in this 
research study.  Upon verbal consent from the patient to the oncologist, the oncologist collected 
the patient’s e-mail address and phone number for the researcher to make contact.  The 
researcher then called each potential participant to explain the Participant Screening Form 
(Appendix D), and explained that the research would be conducted on a volunteer basis.  Further, 
the patients were informed that if they participated in the study to its completion, they would 
receive a $25 gift card.  The researcher sent an e-mail with the Participant Screening Form 
(Appendix D) for each patient and secure attachment to complete and to select a secure 
attachment to participate.  Upon review of the Participant Screening Form (Appendix D), the 
accepted patients were considered study participants.  This process was repeated for each new 
participant.  Study enrollment was open for two months, in order to ensure that all participants 
begin the study within a reasonably similar time frame.  The researcher in this study also served 
as the advisor and / or facilitator for this study.   
Secure attachment.  Once a non-Hodgkin’s lymphoma patient was accepted into the 
study, the researcher contacted the identified secure attachment provided by the patient on the 
Participant Screening Form (Appendix D) by phone.  The researcher called the secure attachment 
to explain the Participant Screening Form (Appendix D), and then sent the Secure Attachment 
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Protocol Form (Appendix E) for the secure attachment to review and sign via email.  The secure 
attachment was also informed of the volunteer basis of the study. 
Data Collection Procedures 
The researcher assigned patients involved in this study a confidential identification 
number to ensure anonymity and aid in data organization throughout the duration of the study.  
Upon receiving a signed copy of the informed consent (Appendix C), all participants and secure 
attachments completed the Participant Screening Form (Appendix D) to determine whether a 
secure attachment was present.  Patients who reported the presence of a secure attachment—who 
could also attend the CT scan meeting and each chemotherapy measure—were selected for the 
study.   
Measurements of the STAI (Speilberger et al., 1983) scores were recorded by the secure 
attachment across seven time points.  The STAI (Speilberger et al., 1983) was administered 30 
minutes through each chemotherapy treatment and after the completion of the CT scan meeting 
with the participant’s oncologist.  The researcher chose for the assessment to be administered 30 
minutes after the start of treatment, as some of the chemotherapy drugs make patients feel tired, 
and the researcher did not want to risk participants resting during times of measurement. 
Participant one underwent a B-design where measurements consisted of the intervention of a 
secure attachment present without holding hands across all time points.  Treatments occurred 
daily for a week and are shown as time points one through five and seven.  The CT scan meeting 
was taken at time point six, where the participant received the results at the Mid-South oncology 
center.  Treatment began on a Monday, and the participant received two treatments in the same 
day: recorded as time points one and two.  The first chemotherapy treatment, labeled as time 
point one, was recorded on a Monday at the primary Mid-South oncology center; the participant 
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then left the facility and traveled to the affiliated hospital to receive an afternoon treatment, 
indicated by time point two.  Time points three, four, five, and seven were measured once a day 
until treatment concluded on Friday.  Time point seven was recorded at the Mid-South oncology 
center following the CT scan meeting.   
Participant two was directed under a B-A design where measurements consisted of the 
intervention of a secure attachment present while holding hands for the CT scan meeting and 
then the first three chemotherapy measures.  Next, participant two completed the last three 
chemotherapy measures without holding hands.  The CT scan meeting was held the week prior to 
the start of treatment.  Treatments occurred daily for a week and are shown as measures two 
through seven.  The participant received two treatments in the same day, which are recorded as 
time points two and three.  The first chemotherapy treatment (time point two) was recorded on a 
Monday at the primary Mid-South oncology center, and the participant would then exit the 
facility with the secure attachment and travel by car to the affiliated hospital to receive an 
afternoon treatment, followed by four single daily treatments; Friday was the last treatment 
received back at the Mid-South Oncology center.   
Participant three was measured under an A-B design, where Phase A consisted of the CT 
scan meeting and the first three chemotherapy measures without holding hands with a secure 
attachment.  Phase B consisted of the last three treatments holding hands with a secure 
attachment.  Participant three received treatment on Wednesdays for three weeks and then had 
the fourth week off treatment.  The CT scan meeting was recorded the week prior to the start of 
treatment.  All time points were measured at the Mid-South oncology setting. 
Across all groups, 30 minutes after the chemotherapy began, the secure attachment began 
the STAI (Speilberger, et al., 1983; Appendix G).  The secure attachment, in compliance with the 
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Secure Attachment Protocol Form (Appendix E), recorded the participant’s scores.  As 
circumstances of the treatment process can vary, given extraneous or uncontrollable variables, 
the secure attachment completed the Post Session Questionnaire (Appendix F) to identify any 
variation from the Secure Attachment Protocol Form (Appendix E) or unforeseen circumstances 
when recording anxiety.  The Post Session Questionnaire (Appendix F) enabled the secure 
attachment to explain how the non-Hodgkin’s lymphoma participant’s anxiety may be affected in 
circumstances including but not limited to: the death of a family member, loss of job, 
relationship distress, and financial distress related to insurance, or seeing another patient 
receiving treatment.   
The researcher has utilized the term time point, to refer to the recorded measures across 
phases of each single-case design.  As each participant underwent a different single-case design, 
attended the CT scan meeting at a different time, and utilized the intervention of hand holding 
within different phases, the time point recorded merely symbolized the first through seventh 
measure.  Thus, the first STAI (Speilberger et al., 1983) recorded, regardless if it was a treatment 
or CT scan meeting, is placed within time point one, and so-forth.  The secure attachment 
recorded the participant’s scores using their dominant writing hand, while holding hands with the 
participant with the opposite hand.  Participants were instructed to continue holding hands 
throughout the entirety of the treatment, and to note in the Post Session Questionnaire (Appendix 
F) if any deviation occurred.  All assessments completed were returned to the nursing staff; the 
assessments were then kept in a secure and confidential file for the researcher to retrieve.  The 
nursing staff was not directly involved in the study and therefore could not explain any 
information to the participant, or answer questions about the study when results were completed.  
The secure attachment was present at each measurement point for all participants.  To better 
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understand the process each group was to follow, instructions from the informed consent 
(Appendix C) are provided in the following sections.  
Participant one. Participant one went through all seven measures while holding hands 
with a secure attachment.  Participant one followed the following detailed protocol within the 
informed consent.  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment and at the completion of the CT scan meeting. 
3. The STAI will be given at chemotherapy treatments 1, 2, 3, 4, 5, and 6.  
4. Hold hands with your secure attachment throughout every treatment. 
5. The STAI will be given after your CT scan meeting with your oncologist. 
6. Hold hands with your secure attachment during the meeting. 
7. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
8. All results will be collected. 
Participant two. Participant two went through the first four measures holding hands.   
During the last three measures, the participant did not hold hands.  The detailed protocol listed in 
the informed consent form for participant two was:  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment and at the completion of the CT scan meeting. 
3. The STAI will be given at chemotherapy treatments 1, 2, 3, 4, 5, and 6.  
4. Hold hands with your secure attachment throughout treatments 1, 2, and 3. 
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5. Do not hold hands with your secure attachment throughout treatments 4, 5, and 6. 
6. The STAI will be given after your CT scan meeting with your oncologist. 
7. Hold hands with your secure attachment during the meeting. 
8. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
9. All results will be collected. 
Participant three.  Participant three went through the first four measures without 
holding hands.  During the last three measures, the participant was instructed to hold hands.  The 
detailed protocol listed in the informed consent form for participant three was:  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment and at the completion of the CT scan meeting. 
3. The STAI will be given at chemotherapy treatments 1, 2, 3, 4, 5, and 6.  
4. Do not hold hands with your secure attachment throughout treatments 1, 2, and 3. 
5. Hold hands with your secure attachment throughout treatments 4, 5, and 6. 
6. The STAI will be given after your CT scan meeting with your oncologist. 
7. Do not hold hands with your secure attachment during the meeting. 
8. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
9. All results will be collected. 
Any deviation from the group instructions was recorded in the Post Session Questionnaire 
(Appendix F).  
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Analysis of Data 
All participants were analyzed using the following methods when appropriate: comparing 
participants’ state and trait anxiety trends, assessing the state anxiety cutoff score of 39 (Julian, 
2011), conducting visual analysis, using both percentage of non-overlapping data (PND) and 
percentage of all non-overlapping data (PAND) for statistical analysis, making reference to any 
adverse events that occurred, and conducting a follow-up interview.  Participant one was 
excluded from the statistical analysis of PND and PAND, as there was not a baseline measure 
recorded.  The secure attachments scored the STAI (Speilberger, et al., 1983; Appendix G) by 
hand as instructed within the assessment tools.  The researcher collected the results in an Excel 
file, and made calculations, graphs, and tables for each participant.  Table 1 provides information 
regarding time points recorded per phase for each participant’s protocol throughout the study. 
Table 1 
Participant Protocol Across Phases 
       Baseline (A-Phase)     Intervention (B-Phase)         Total       
Participant             (n measures)        (n measures)    (n measures)  
One                                                                    0    7                 7 
Two                 3        4              7  
Three           4        3            7  
         
Note: n measures are the total recorded measures per phase.  
State and Trait Anxiety Trend Comparison 
 Speilberger et al. (1983) have defined trait anxiety as traits of one’s personality, which 
describe individual differences when compared to immediate state anxiety.  Thus, each 
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participant’s trait anxiety scores should serve as a measured normative personality trait. If the 
state anxiety scores are above the trait anxiety scores, it is evident that the situation causing the 
anxiety is greater than that of the person’s personality trait.  If the state anxiety scores are lower 
than the individual’s trait anxiety scores, then the person is experiencing less anxiety compared 
to their personality norm. The researcher compared each participant’s state and trait anxiety 
scores across time points.   
State Anxiety Cutoff Score 
To determine clinical significance for each participant, the researcher determined a cutoff 
score.  The range of scores for the STAI (Speilberger et al., 1983) is 20-80 for each subtest, with 
the higher score indicating greater anxiety (Julian, 2011).  Julian (2011) recommended that a 
cutoff score of 39-40 should be used to detect clinical significance symptoms for the state-
anxiety of a participant; for the purposes of the present study, the researcher selected a cutoff 
score at or below 39 to demonstrate scores above represent state anxiety clinical significance.  
The cutoff score was used to help remove subjective interpretation of the results, particularly for 
participant one, as there was not a baseline measure to compare.  The scores for each 
participant’s trait anxiety reflect what their normal anxiety levels would be if the threatening 
situation (in this case, treatment) were removed.   
Visual Analysis 
The researcher employed visual analysis of graphed data to determine intervention 
effectiveness.  Each participant was analyzed independently, although commonalities and 
differences between participants became evident through visual inspection.  As mentioned 
previously, participant one was measured under a B-design; as Engel and Schutt (2013) 
explained, in this case, the actual improvement cannot be attributed to the intervention, as there 
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may be threats to internal validity.  Recognizing this issue, the researcher used the cutoff score as 
a comparison across all measures for participant one.  For participants two and three, to produce 
reliable and valid visual analysis results, it was necessary to meet a number of baseline data 
standards within Phase A (Smith, 2012).  Baseline qualification standards, at a minimum, require 
Phase A to meet the following stipulations: be relatively stable and free of significant trend with 
focus in the opposite hypothesized direction of intervention, display minimal overlap of data 
with subsequent phases, and provide ample sampling of behavior to meet constraints (Franklin, 
Gorman, Beasley, & Allison, 1997; Parsonson & Baer, 1978).   
To provide justification for the selection of visual analysis, Parker, Cryer, and Byrns 
(2006) suggested that visual analysis could accomplish more than statistical analysis in single-
case designs.  Currently, there is no statistical technique that can concurrently reflect data 
variability, trend degree and trend, mean levels and changes, embedded cycles (e.g., weekly), 
and abrupt changes in results at the point of intervention (Parker et al., 2006).  Visual analysis 
allows researchers to detect the direction of change, specifically how the intervention influenced 
the effect size (Parker et al., 2006).  Moreover, the standard use of visual analysis for single-case 
study designs, and which was used for this research, involves examining the overall graph and 
considering the following four steps and six outcome-measure features (Kratochwill et al., 2013; 
Parsonson & Baer, 1978).  Step one is documentation of a predictable and stable baseline pattern 
(Kratochwill et al., 2013).  Step two requires examining within-phase data patterns through the 
assessment of level, trend, and variability (Kratochwill et al., 2013).  Step three consists of 
comparing the data in the baseline phase to that in the intervention phase to assess whether 
manipulation of the independent variable produced an effect (Kratochwill et al., 2013).  This is 
done by assessing level, trend, variability, the immediacy of effect, overlap, and consistency of 
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data patterns between phases (Fisher, Kelley, & Lomas, 2003; Hersen & Barlow, 1976; Kazdin, 
2011; Kennedy, 2005; Kratochwill et al., 2013; Parsonson & Baer, 1978).  Ray (2015) defined 
immediacy of the effect as how quickly the intervention demonstrates an effect.  Specifically, the 
focus is on the change in the last three data points in one phase and first three in the intervention 
phase (Kratochwill et al., 2013); the more rapid the effect, the more persuasive the results are 
due to the manipulation of the independent variable (Kratochwill et al., 2013).  Overlap involves 
the comparison of data from Phase B with the data that overlaps with data in Phase A (Ray, 
2015).  Kratochwill et al.  (2013) specified that the smaller or, conversely, the greater the non-
overlap, the more convincing the evidence of an effect.  This information was calculated using 
both percentage of non-overlapping data and percentage of all non-overlapping data, which is 
explained in the following statistical analysis section.  Lastly, consistency of data patterns across 
similar patterns includes analyzing data from all phases within the same condition, and 
examining the consistency in the data patterns from similar conditions.  Step four compares 
level, trend, and variability between subjects to verify replication of effect (Kratochwill et al., 
2013).  Given participant one’s absence of a baseline measure, the researcher only compared 
Phase B.  The researcher used this basic effect measure for participants two and three. 
Individual Participant Statistical Analysis 
 Participant one did not meet the criteria of having a baseline measure to compare and was 
excluded from statistical analysis.  Participants two and three were measured under baseline and 
intervention conditions, and have a different setting measure (CT scan meeting).  Therefore, the 
researcher desired to account for any possible variability in the data.  The researcher measured 
statistical analysis for state and trait anxiety across all time points (one through seven).  
Additionally, the researcher conducted statistical analysis for state and trait anxiety across only 
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the time points where a participant received treatment (two through seven).  This was necessary 
to help differentiate data specific to research questions.   
Percentage of non-overlapping data.  In addition to visual analysis, the researcher used 
a common non-regression approach used in single-case research called the percentage of non-
overlapping data (PND; Scruggs & Mastropieri, 2001).  Calculating the PND allows for a 
meaningful index of intervention effectiveness (Scruggs & Mastropieri, 2001).  To calculate 
PND, the researcher calculates the percentage of recorded data points during the intervention 
phase(s) that surpasses the highest value in the baseline phase (Scruggs & Mastropieri, 1998).  
However, for participants two and three, the researcher measured the percentage of data points in 
the intervention phase that fell below the lowest baseline measure.  The step-by-step procedure 
used to calculate PND included: 
• Identify intended change (increase or decrease in scores) in the data from baseline 
phase to treatment phase 
• Identify the greatest or least datum point in the baseline phase (on the therapeutic 
side).  Select the greatest point of goal of treatment is to  decrease scores and the 
least if goal is to increase scores.   
• Draw data line from the datum point identified in Step 2 that extends  through the 
treatment phase.   
• Count the number of data points above or below the line (on the  therapeutic side) 
drawn in Step 3.   
• Divide the count from Step 4 by the total number of data points in the  treatment 
phase 
• Interpret the effect size (Lanz, 2013).  
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Percentage of all non-overlapping data.  While the PND method offers important 
results, percentage of all non-overlapping data (PAND) uses a ratio-based analysis within the 
non-overlap data between phases (Lenz, 2013).  When at least 20 observations are recorded, the 
use of PAND is a way to reveal a robust measure of effect size (Lenz, 2013; Parker, Hagan-
Burke, & Vannest, 2007).  While this study does not meet the criteria of at least 20 observations, 
PAND did produce different results than the PND method and the researcher determined it to be 
useful.  Lenz (2013) explained that using PAND allows the researcher to create equal marginal 
proportions not achieved using PND and percentage of data exceeding the median (PEM).  
Parker et al. (2007) also noted that limitations of the PAND method are similar to PND, as it 
includes sensitivity to outliers and the inability to control for positive trends found in the baseline 
phase (Lenz, 2013).  The researcher used the following procedure for calculating PAND: 
• Identify intended change  
• Sum the total number of data points in baseline and treatment phases 
• Draw a line to identify the minimum number of data points needed to  eliminate the 
overlap between the baseline and treatment conditions 
• Count the number of data points removed from the treatment condition  to eliminate 
all overlap 
• Subtract the total number of data points removed to eliminate overlap  from the 
total number of data points 
• Divide the value from Step 5 by the total number of data points identified  in Step 2 
• Interpret the effect size (Lanz, 2013).   
Scruggs and Mastropieri (1998) have suggested that PND and PAND scores above .90 are very 
effective treatments; scores ranging from .70 to .89 are moderately effective treatments; scores 
63 
ranging from .50 to .69 are debatably effective; and scores less than .50 are deemed ineffective.  
Thus, the researcher was seeking scores within the very effective range to help determine 
significance for the effects.     
Analysis of Within-Condition and Between-Conditions 
Lane and Gast (2013) provided a step-by-step guide for calculating within-conditions and 
between-conditions analysis; for the purposes of the present study, the researcher used this 
method for all participants.  The researcher used the following guide to calculate the within-
condition analysis:  
• Step 1 is assessing a letter to each condition (i.e., A-B-C notation)  
• Step 2 is counting the number of sessions for each condition 
• Step 3 is calculating the mean, median, range, and stability envelope of data for each 
condition 
• Step 4a is calculating level change within each condition 
• Step 4b is calculating the difference between the first and last value within each 
condition 
• Step 5 is calculating trend using the split-middle method of trend estimation 
• Step 6 is calculating the percent of data points within the stability envelope for each 
condition  
• Step 7 is using the freehand method to evaluate data paths (Lane & Gast, 2013). 
To calculate between-condition analysis, the researcher used the following guide: 
• Step 1 is determining the number of variables that changed between conditions with a 
focus across conditions 
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• Step 2 is identifying trend direction across adjacent conditions as accelerating, 
decelerating, or zero-celerating  
• Step 3 is comparing the decision from Step 6 from the within-condition analysis 
section to Step 2 of the between-condition analysis section 
• Steps 4a-d are evaluating (a) relative, (b) absolute, (c) median, and (d) mean level 
change 
• Steps 5a-b are calculating percent of non-overlapping data (PND; Lane & Gast, 2013) 
and percent of all non-overlapping data (PAND).  
However, limitations are present within these methods.  Lane and Gast (2013) have explained 
that relative level change focuses on median change but does not account for immediacy of 
change.  Further, absolute level change only focuses on immediacy of change from the final 
baseline measure to the first intervention measure and excludes other measures recorded (Lane & 
Gast, 2013).  Therefore, the researcher chose to include both absolute level change and mean 
level change too account for both the immediacy of the effect and potential outliers (Lane & 
Gast, 2013).  
The researcher analyzed participant one using the within-conditions of absolute level 
change of Phase B (Lane & Gast, 2013).  Within the intervention phase, the researcher evaluated 
level, trend, and variability for state and trait anxiety under three circumstances: time points only 
recorded during treatment prior to the CT scan meeting (time points one through five), time 
points only recorded during treatment (time points one through five and seven), and across all 
time points, which includes the CT scan measure (time points one through seven).  The purpose 
of this method was to differentiate the effects the CT scan meeting may have had on time points 
before and after.  As no baseline measures were recorded for participant one, visual analysis was 
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limited.  Using the guide provided by Lane and Gast (2013), the researcher calculated only 
absolute level change for participant one, but absolute and mean level change for participants 
two and three.  For participants two and three, the researcher completed visual analysis and 
statistical analysis.  
Adverse Events 
 The researcher instructed each participant to follow the instructions within the Secure 
Attachment Protocol Form (Appendix E).  If any variation or violation occurred, the participant 
was asked to have the secure attachment individual complete the Post Session Questionnaire 
(Appendix F) to account for circumstances.  These responses were completed after each of the 
seven measures recorded and would help the researcher identify any scores that may be 
influenced beyond the control of the participant during treatment.   
Follow-up Interview  
 After each participant completed the study, the researcher conducted a brief unstructured 
follow-up interview over the phone.  Questions were informal and related to the patients’ overall 
experience in the study, how the patient felt hand holding impacted their anxiety during 
treatment compared to the absence of hand holding (excluding participant one), and any closing 
thoughts they wanted to offer.  Participants were informed that they did not have to participate in 
the interview.  The researcher decided to use a follow-up interview to better understand the 
participants’ narrative experience to compare this with the data collected.  Given the limited data 
points collected for each participant, the interview provided the researcher with concrete 
information to assist in the analysis of data.    
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CHAPTER IV: 
RESULTS 
The participants’ secure attachments recorded measures as instructed on the Secure 
Attachment Protocol Form (Appendix E) at each time point; any deviations that occurred were 
recorded on the Post Session Questionnaire (Appendix F).  Results for each participant were 
analyzed independently using: a state and trait anxiety trend comparison, the state anxiety cutoff 
score of 39, visual analysis, both PND and PAND for statistical analysis, and a follow-up 
interview.  Participant one did not record any baseline measures and was excluded from 
statistical analysis.  This chapter consists of focus on each participant independently, as the 
researcher used multiple single-case designs for the purposes of this study.  Table 2 provides the 
means, standard deviations, percentage of non-overlapping data (PND), and percentage of all 
non-overlapping data (PAND) for state and trait anxiety scores across each phase.   
Table 2 
Mean, Standard Deviation, PND, and PAND Scores for All Participants Across Phases 
                                                State Anxiety 
Participant Ma SDa Mb SDb PND PAND 
One   29.28 5.98   
Two 42.33 0.57 26.25 6.23 1.00 1.00 
Three 52.75 1.70 36.33 1.52 1.00 1.00 
Note: Ma = mean of baseline phase; Mb = mean of intervention phase; SDa = standard deviation 
of baseline phase; SDb = standard deviation of intervention phase; PND = percentage of non-
overlapping data; PAND = percentage of all non-overlapping data.  Decreased average scores 
indicate improvement.  
 
Table 3 provides the means, standard deviation, PND, and PAND for trait anxiety within each 
phase.  
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Table 3 
Mean, Standard Deviation, PND, and PAND Scores for All Participants Across Phases 
 Trait Anxiety 
Participant Ma SDa Mb SDb PNDt PANDt 
One   33.85 4.27  
Two 26.00 3.00 21.75 2.06 0.50 0.71 
Three 50.00 0.81 49.66 1.52        0.33 0.33 
       
Note: Ma = mean of baseline phase; Mb = mean of intervention phase; SDa = standard deviation 
of baseline phase; SDb = standard deviation of intervention phase; PND = percentage of non-
overlapping data; PAND = percentage of all non-overlapping data.  Decreased average scores 
indicate improvement.  
 
Participant One 
Participant one is a 61-year-old male who was diagnosed with diffuse B-cell non-
Hodgkin’s lymphoma.  Participant one completed a B-design single-case design where the 
intervention of hand holding with a secure attachment was present for time points one through 
seven.  All measures were recorded by the secure attachment over the course of five days.  The 
raw data of state anxiety are as follows: 30, 24, 39, 29, 31, 30, and 22 (M = 29.28, SD = 5.98).  
The raw data of trait anxiety are as follows: 36 34, 42, 31, 34, 30, and 30 (M = 33.85, SD = 
4.27). 
State and Trait Anxiety Trend Comparison   
Initial evaluation of the state and trait anxiety results demonstrated that data were 
paralleled across all time points; as state anxiety increased or decreased, so did trait anxiety.  The 
intervention phase (B) is noted as the B-Phase within the graph (see Figure 1).  State anxiety 
decreased more than trait anxiety at time points two and seven.  Lastly, at the CT scan meeting 
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(time point six), the scores were matching.  Figure 1 provides a graphical illustration of data 
collection for participant one within the respective single-case design.    
Figure 1. Participant one’s trend comparison for state and trait anxiety. 
State Anxiety Cutoff Score 
All state anxiety results remained under the cutoff score of 39, with the exception of the 
third chemotherapy treatment (time point three) with a score of 39, demonstrating the absence of 
state anxiety clinical significance (Julian, 2011).  Results based on the cutoff score indicate 
clinical improvement for the use of hand holding with a secure attachment.   
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Figure 2. Participant one’s state anxiety cutoff score. 
Visual Analysis   
Within visual analysis of the data, absolute level change of state anxiety results are as 
follows: time points one through five showed an increase (+1) in anxiety; comparing all 
treatment time points, there was a decrease in anxiety (-8); and across all time points, there was a 
decrease in anxiety (-8).  Absolute level change of trait anxiety results are as follows: time points 
one through five showed a slight decrease in anxiety (-2); across all treatment time points, there 
was a decrease in anxiety (-6); and across all time points there was a decrease in anxiety (-6).  
Trend analysis indicated that there was a decreasing trend for both state and trait anxiety when 
measured across all time points and all treatments.  There was a small increase in trend in the 
first five treatment time points.  Analysis of variability showed moderate variability across all 
time points for both state (M = 29.28, Range = 22 – 39, SD = 5.98) and trait anxiety (M = 33.85, 
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Range = 30 – 42, SD = 4.27).  Variation specifically occurred between time points two through 
four for both state and trait anxiety, indicating a potential adverse event.   
Figure 3. Participant one’s linear comparison for state and trait anxiety. 
Adverse Events  
When reviewing the Post Session Questionnaire (Appendix F), the researcher identified 
the presence of adverse events.  The participant recorded consistent interruptions by medical 
staff for monitoring, and that there were “…nurses interruptions with lights, etc.” throughout 
treatment, which caused the participant to break hand holding with the secure attachment.  The 
secure attachment individual expressed that she was “Working hard on getting [the participant] 
to relax.”  The necessary interruptions by the medical staff may account for this variation in data.  
The participant also revealed that the CT scan meeting was a “very emotional, but positive” 
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experience, which may account for the decrease in time point seven for state anxiety and stability 
in trait anxiety.  Results of the CT scan meeting reveled no evidence of disease but that 
maintenance treatment would continue.  At the third time point, the participant noted that he 
struggled to sleep the night before and was not feeling well.  Specifically, the participant wrote: 
“It was a rough night, and my body is going through a lot…loss of hair and weight.”  This 
information was important to note as it may have skewed the data.  Moreover, while this may be 
similar to what other cancer patient’s experience, it appears to have had an impact on the 
participant’s anxiety as indicated by the state (39) and trait (42) anxiety scores. 
Follow-up Interview  
During the follow-up interview, the participant explained, with regard to the overall 
experience of hand holding during treatment, that: “It was such a blessing to have my wife with 
me and for her to experience this with me by holding hands.  Even after treatment ended, we 
would continue to hold hands at home any time I felt anxious.”  The researcher asked the 
participant how hand holding impacted his anxiety during treatment, and the participant stated: 
“You know, I got to say it was quite relaxing….it brought me a sense of calm and rest while I 
received treatment….I knew I was safe with my wife holding my hand.”   
Participant Two 
Participant two is a 70-year-old female who was diagnosed with diffuse B-cell non-
Hodgkin’s lymphoma.  Participant two completed a B-A single-case design where the 
intervention of hand holding with a secure attachment was present for time points one through 
four.  For time points five through seven, baseline measures were taken without hand holding, 
but the secure attachment was present in the treatment room recording results.  All measures 
were recorded by the secure attachment daily for five days.  The raw data of state anxiety are as 
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follows: 33, 30, 22, 20, 43, 42, and 42 (M = 33.14, SD = 9.67).  The raw data of trait anxiety are 
as follows: 24 20, 20, 23, 23, 26, and 29 (M = 23.57, SD = 3.20). 
State and Trait Anxiety Trend Comparison 
Participant two displayed a steady increasing trend across all trait anxiety time points.  
The intervention phase (B) is noted as the B-Phase, and the baseline phase (A) is labeled as A-
Phase (see Figure 4).  A noticeable variation of trait anxiety scores occurred between time points 
one (24) and two (20), which is to be expected as these are two different conditions: the CT scan 
meeting and treatment.  Despite the change in treatment setting, the trait anxiety during treatment 
continued to increase over time.  Time point one was measured in a typical doctor-patient 
meeting room where the participant received the results of the CT scan.  Time point two was 
taken within the chemotherapy room at the Mid-South oncology setting.  Time points three 
through seven were recorded within the affiliated chemotherapy hospital setting.  Assessing the 
trend of state and trait anxiety through visual analysis, time points one and two parallel (Trait – 
24, 20; State – 33, 30) each other before closing in at time point three (Trait – 20; State – 22) and 
crossing at time point four (Trait – 23; State – 20).  These measures were taken while the 
intervention of hand holding with a secure attachment occurred.  The state anxiety scores greatly 
declined with the presence of the intervention.  This is important to note, as the trait anxiety of 
the participant was lower than the state anxiety across all measures except time point four.  After 
the intervention was removed at time points five through seven, the state anxiety steadily 
declined as the trait anxiety increased.  This comparison of trait anxiety may indicate that the 
participant became increasingly anxious as a personality trait within the cancer treatment setting.  
When receiving treatment, scores are manipulated given the presence or absence of the 
intervention.  Therefore, the intervention appears to assist the participant’s state anxiety towards 
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her trait anxiety, while the absence of the intervention both increased her trait anxiety and her 
state anxiety (see Figure 4).   
Figure 4. Participant two’s trend comparison for state and trait anxiety. 
State Anxiety Cutoff Score 
As recommended by Julian (2011), a cutoff score of 39-40 should be used to detect 
clinical significance symptoms for the state-anxiety of a participant.  The cutoff score at or below 
39 was used to determine intervention significance for participant two.  The raw data for the 
intervention phase (B) are as follows: 33, 30, 22, and 20; scores for the baseline phase (A) are as 
follows: 43, 42, and 42 (see Figure 5).  Results based on the cutoff score indicate state anxiety 
clinical significance for A-Phase but not B-Phase.  It is also important to note that the lack of the 
intervention in A-Phase, where the secure attachment was present but not holding the patient’s 
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hand, the patient’s mood was stable across time points five through seven.  This stability 
indicates that the effect of a secure attachment’s presence was useful, but did not produce as 
significant an effect for the participant as holding hands during treatment.    
Figure 5. Participant two’s state anxiety cutoff score. 
Visual and Statistical Analysis 
As this participant completed measures under a B-A single-case design, significance is 
based on the results of the A-phase trend.  For state anxiety, level analysis revealed a mean 
increase from the intervention phase to the baseline phase (B-Phase M = 26.25; A-Phase M = 
42.33).  Level analysis for trait anxiety revealed a mean increase across phases (B-Phase M = 
21.75; A-Phase M = 26).  State anxiety changed from a decelerating-improving trend during the 
intervention before a significant increase in anxiety and minimal decelerating-improving trend 
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during the baseline measures.  Trait anxiety changed from a decelerating-improving trend during 
the intervention to accelerating-deteriorating trend during the baseline.  Analysis of variability 
revealed moderate variability for state anxiety (M =33.14; Range = 20 – 44; SD = 9.66) and 
minimal variability for trait anxiety (M = 23.57; Range = 20 – 26; SD = 3.20) across the 
intervention and baseline phases.   
However, a large difference in scores for state anxiety appeared within the transition 
between phases, indicating the potential and immediate effect of the intervention on the 
participant.  Compared to the last data point in the intervention phase of state anxiety, data 
noticeably increased, starting with the first data point in the baseline phase, indicating an 
immediate treatment effect.  Within trait anxiety, however, the last data point of the intervention 
and the first data point of the baseline were equal.  It was not until the second baseline measure 
that results displayed an effect on the participant’s trait anxiety.  Through visual analysis, the 
researcher determined that the results do not indicate overlap of data for state anxiety and 
indicate low overlap for trait anxiety.  These results indicate a large treatment effect for state 
anxiety (PND = 1.0, PAND = 1.0).  For trait anxiety, there is debatably any effect present under 
the PND analysis and moderate effectiveness under the PAND analysis (PND = .50; PAND = 
.71).  Therefore, the data indicate that hand holding was 100% effective in reducing the 
participants’ state anxiety and roughly 71% effective in reducing the participants’ overall trait 
anxiety (see Figure 6).   
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Figure 6. Participant two’s linear comparison for state and trait anxiety. 
Adverse Events   
As reported on the Post Session Questionnaire (Appendix F), the participant did note 
adverse events.  The purpose of mentioning the adverse events is to account for extraneous 
variables, which may impact or skew the data and the effectiveness of the intervention.  First, the 
participant noted that, during the first chemotherapy treatment (time point two), the oncologist 
came in to do an exam of the participant.  This was unexpected by the participant and created 
concern and may have impacted the state anxiety score (30).  However, this was to see if the 
participant was experiencing any complications with the treatment.  During the same treatment, 
the participant had to leave for additional tests to be done, and recorded that she discovered a 
friend had also been diagnosed with cancer prior assessment administration.  Second, despite 
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participant two mentioning that her car had broken down on the day of the third chemotherapy 
treatment (time point four), her anxiety scores were lower in state anxiety but displayed an 
increase in trait anxiety (state anxiety = 20; trait anxiety = 23).  Lastly, on the first day of 
baseline measures where hand holding did not occur (state anxiety = 43; trait anxiety = 23), the 
participant noted that her car broken down again.  Despite these situations occurring, the 
participant followed the protocol as intended within the study.    
Follow-up Interview 
The researcher asked participant two if she would be willing to provide any comments 
about her experience throughout the study; her responses indicate that holding hands during 
treatment was very helpful for both her and her husband.  Specifically, the participant stated: 
“Having my husband there to hold my hand brought me comfort, and I even convinced other 
patients to start doing the same.”  Participant two even mentioned that the effects of hand 
holding with her secure attachment had a calming effect for the secure attachment during 
treatment.  The participant was asked to explain the increase in state anxiety experienced in the 
baseline measures immediately following the removal of hand holding.  The participant stated: 
“Despite having good results [no evidence of disease], the treatment was difficult to sit 
through…I didn’t feel as calm as when we held hands….I felt safe with him there in the room 
and all, but it’s just comforting to hold his hand during these treatments.”  As the participant was 
given further treatments by her oncologists for management, the researcher encouraged the 
participant to continue to use hand holding to help her anxiety during treatment.   
Participant Three 
Participant three is a 71-year-old male who was diagnosed with B-cell follicular non-
Hodgkin’s lymphoma.  Participant two completed an A-B single-case design where the 
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intervention of hand holding with a secure attachment was absent for time points one through 
four, but the secure attachment was present in the treatment room recording results for three 
consecutive weeks and off for one before repeating.  For time points five through seven, 
measures were taken with the intervention of hand holding with a secure attachment.  The raw 
data of state anxiety are as follows: 55, 52, 53, 51, 38, 30, and 28 (M = 43.85; SD = 11.56).  The 
raw data of trait anxiety are as follows: 50, 49, 50, 51, 43, 35, and 33 (M = 44.42; SD = 7.61). 
State and Trait Anxiety Trend Comparison 
Participant three displayed a steady flat trend across all trait anxiety time points in phase 
A and a decreasing trend in phase B.  The intervention phase (B) is noted as the B-Phase, and the 
baseline phase (A) is labeled as A-Phase within the graph (see Figure 7).  Time point one was 
measured in a typical doctor-patient meeting room where the participant received the results of 
the CT scan.  Time points two through seven were taken within the chemotherapy room at the 
Mid-South oncology setting.  Looking at trait and state anxiety, time points one through three 
parallel (Trait – 50, 49, 50; State – 55, 52, 53) each other before measuring the same at time 
point four (Trait – 51; State – 51).  The first four time points were taken without the use of the 
intervention of hand holding with a secure attachment.  Within the intervention phase (B-Phase), 
the state and trait anxiety both began to decrease.  The higher scores of trait anxiety may indicate 
that the participant experiences anxiety as a norm, related to the diagnosis of PTSD.  During 
treatment, the participant’s scores indicate that the intervention improved state anxiety, despite 
the neutral trend in trait anxiety (see Figure 7).   
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Figure 7. Participant three’s trend comparison for state and trait anxiety. 
State Anxiety Cutoff Score 
The researcher used the cutoff score of 39 to determine clinical significance for 
participant three’s state anxiety (Julian, 2011).  The raw data for the baseline phase (A) are as 
follows: 55, 52, 53, 51; scores for the intervention phase (B) are as follows: 38, 30, and 28 (see 
Figure 8).  Results based on the state anxiety cutoff score of 39 indicate clinical significance for 
A-Phase but not B-Phase.  Noticeably, participant three’s state anxiety was relatively stable in 
Phase A, though declining in Phase B.  For this individual, the presence of a secure attachment 
did provide comfort in alleviating anxiety, but not to the same extent as when holding hands with 
the secure attachment (see Figure 8). 
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Figure 8. Participant three’s state anxiety cutoff score.  
Visual and Statistical Analysis 
As this participant completed measures under an A-B single-case design, significance is 
based on the results of the B-phase trend.  For state anxiety, level analysis revealed a mean 
decrease from the baseline phase to the intervention phase (A-Phase M = 52.75; B-Phase M = 
32).  Level analysis for trait anxiety revealed a mean decrease across phases (A-Phase M = 50; 
B-Phase M = 37).  State anxiety revealed a minimal variable decelerating-improving trend in 
baseline measures; after the introduction of the intervention, the trend continued in a 
decelerating-improving path.  Trait anxiety displayed limited variability with an accelerating-
deteriorating trend in baseline measures where, upon introduction of the intervention, there was a 
decelerating-improving trend.  Analysis of variability revealed moderate variability for state 
anxiety (M =43.85; Range = 28 – 55; SD = 11.56) and moderate variability for trait anxiety (M = 
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44.42, Range = 33 – 51, SD = 7.61) across both phases.  Compared to the last data point in the 
baseline phase of state anxiety (state anxiety = 51), data noticeably decreased, starting with the 
first data point in the intervention phase (state anxiety = 38); this indicates an immediate 
treatment effect.  Trait anxiety displayed a significant immediate effect across phases (Phase A = 
51; Phase B = 43), indicating immediate effect across phases.  Through visual analysis, the 
researcher determined that there was no overlap of data for state anxiety and low overlap for trait 
anxiety.  These results indicate a large treatment effect for state anxiety (PND = 1.0; PAND = 
1.0) and similarly for trait anxiety (PND =1.0; PAND = 1.0).  Finally, the data reveals 100% 
effectiveness when utilizing hand holding as an intervention to reduce state and trait anxiety for 
participant three (see Figure 9).  
Figure 9. Participant three’s linear comparison for state and trait anxiety.  
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Adverse Events 
When reviewing the results from participant three’s Post Session Questionnaire 
(Appendix F), the researcher identified adverse events.  During the first chemotherapy measure 
(time point two), the patient fell asleep during treatment; therefore, instead of the participant 
completing the STAI (Speilberger, et al., 1983; Appendix G) at the scheduled 30 minutes after 
the start of treatment, the secure attachment recorded the responses to the STAI (Speilberger, et 
al., 1983; Appendix G) 45 minutes after the start of treatment.  Lastly, the researcher was 
walking the clinic floor towards the research offices and passed the participant randomly by the 
lobby.  The participant explained that another relative was present for treatment three (time point 
four; state anxiety = 51; trait anxiety 51), but that this was not recorded on the Post Session 
Questionnaire (Appendix F).  As the participant had not noted this family member’s presence in 
the treatment room, the researcher made a note to record the event.  The remaining sessions were 
completed as indicated in the protocol. 
Follow-up Interview 
The researcher asked the participant if he would be willing to participate in an interview 
following the completion of the study about his overall experience throughout the study.  
Participant three stated: “I knew what was ahead of me, and I knew the results were good going 
into treatments, but it was nice to have my wife there and to hold her hand.”  The researcher 
asked the participant how he felt when holding hands during treatment compared to his feelings 
in the absence of hand holding.  The participant explained: “This was easy-going all around, but 
I did feel more relaxed when we held hands, but I also felt relaxed when we just sat together.”  
As noted previously, the participant was diagnosed in the past with PTSD; thus, the researcher 
inquired if this had any impact.  Participant three stated: “Yeah my medication keeps me 
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mentally relaxed, but my body still feels tense sometimes.”  The researcher asked if the 
participant felt more tense when hand holding was absent, and he stated: “Yes, so I would just 
sleep or distract myself during treatment…but when we held hands we talked more.”  
Consistency of Data Across Similar Phases 
The final variable for consideration in visual analysis is consistency of data patterns 
across similar phases (Ray, 2015).  Ray (2015) explained that this step in visual analysis is the 
review of replication of phases.  Thus, participants’ baseline and intervention phases are 
discussed to assist in replication of results and to support the credibility of findings (Ray, 2015).   
 Participant one was only measured under the intervention, and may therefore offer 
skewed data compared to participants two and three, who also underwent baseline measures.  In 
comparison of the first four intervention measures of state and trait anxiety, participant one 
displayed more variability, and less of a declining trend than participants two and three.  The CT 
scan meeting measures for participants one and two were completed under the intervention 
phase.  Participant one displayed higher trait anxiety and lower state anxiety at time point six 
compared to participant two’s measure at time point one.  Participant two displayed an 
increasing trend for trait anxiety and decreasing trend for state anxiety within the first four 
measures, while participant three’s last three measures displayed a decreasing trend for both trait 
and state anxiety.  In assessing baseline measures, participant two, within the last three measures, 
and participant three, within the first four measures, displayed similar variability and trends in 
both state and trait anxiety.  For a visual of all participants data compared between phases, see 
Figure 10. 
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Figure 10. Consistency of data between participants and phases. 
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CHAPTER V: 
 
DISCUSSION 
This chapter includes an interpretation of each participant’s results with regard to each 
research question, limitations to the study, its applicability, and methodological implication 
findings.  The chapter concludes with a discussion of areas for future research, specific 
recommendations for counselor educators, and a brief summary.  The purpose of this dissertation 
was to explore how the anxiety levels of non-Hodgkin’s lymphoma patients receiving 
chemotherapy are affected while holding hands with a secure attachment.  This chapter includes 
discussion and future research opportunities to help answer the following research questions:  
(R1): Does hand holding with a secure attachment decrease the state and trait anxiety of 
non-Hodgkin’s lymphoma patients during treatment, as measured by the STAI 
(Speilberger et al., 1983)?   
(R2): Does hand holding with a secure attachment during treatment decrease the state 
anxiety of non-Hodgkin’s lymphoma patients more compared to only having the secure 
attachment present during treatment, as measured by the STAI (Speilberger et al., 1983)? 
(R3): Does hand holding with a secure attachment during treatment decrease the state 
anxiety of non-Hodgkin’s lymphoma patients below the cutoff score of 39, as measured 
by the STAI (Speilberger et al., 1983)? 
The results indicate the following when participants held hands with a secure attachment during 
treatment: (a) there may be a favorable trend comparison between state and trait anxiety, (b) all 
participants’ state anxiety measured at or below the cutoff score of 39, (c) visual analysis and 
statistical analysis indicates possible significant results, and (d) follow-up interviews may have 
revealed a lasting effect for participants.    
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Participant One 
Participant one was measured under a B-design where hand holding with a secure 
attachment occurred in each of the six chemotherapy measures and during the CT scan meeting.  
The purpose of the B-design single-case study was to see the effects, if any, hand holding would 
have on a participant across treatment, and thus serve as an intervention comparison for 
remaining participants.  As participant one did not receive a baseline measure, or the absence of 
hand holding with a secure attachment, research question two was excluded from this discussion.  
Regarding research questions one and three, participant one’s results may indicate that the 
intervention was immediately effective in reducing state anxiety.  Despite the increased scores at 
time point three, there was a decreasing trend in both state and trait anxiety.  Significantly, the 
participant’s state and trait anxiety remained parallel; with the exception of the CT scan meeting 
and time point seven.  This may be attributed to the secure attachment presence and the effects of 
hand holding.  Participant one selected his spouse, who may help the participant’s trait anxiety 
regulate, while hand holding may have helped lower the state anxiety.  Across all measures, state 
anxiety remained below the cutoff score of 39, which reveals the absence of state anxiety clinical 
significance (Julian, 2011).  The participant’s trait anxiety for time points one through five were 
gradually declining when holding hands, despite not having the future prognosis in the CT scan 
meeting.  Participant one completed time points one through five without knowing the effects of 
his treatment and if the prognosis was favorable.  Therefore, to see the state anxiety scores fall 
outside the parameters of clinical significance (Julian, 2011), this is worth mentioning the 
intervention of hand holding may have had an anxiety reduction effect.  Time point seven is also 
important to consider as state anxiety continued to decline and trait anxiety stabilized.  Across all 
measures, it appears that the use of hand holding with a secure attachment was beneficial for this 
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participant and supported within the follow-up interview.  The participant may have maintenance 
treatments throughout life; if this is the case, he indicated during the follow-up interview that he 
plans to hold his wife’s hand during each treatment.    
Participant Two 
 Participant two was studied under a B-A design across time points.  The participant was 
purposely selected given that her CT scan meeting was scheduled to occur before the start of 
treatments.  This was important as it enabled the researcher to record a more accurate 
understanding of treatment effects as the unknown prognosis of disease may have impacted 
participant one.  The CT scan meeting and the first three treatments were measured while 
participant two held hands with a secure attachment.  Following completion of the third 
treatment, the intervention was withdrawn, but the secure attachment remained in the treatment 
room with the participant to record results.  According to the findings in this study, each research 
question was addressed accordingly.  The time points measured with the intervention displayed a 
decrease in state anxiety, but a moderate increase in trait anxiety.  Based on visual analysis, upon 
removal of the intervention, the researcher found that state anxiety greatly increased and then 
minimally declined across the remaining measures.  Trait anxiety continued to increase across 
the last three measures.  As there was an increasing overall trend for both state and trait anxiety, 
it appears that the intervention was effective.  Participant two appeared to be relatively calm, 
evidenced by the trait anxiety measures, but may have experienced more anxiety as treatment 
continued despite the good results from the CT scan meeting.  Therefore, the researcher 
concluded that, despite a good prognosis with treatment, the experience of chemotherapy has a 
negative impact on anxiety (Barre et al., 2015).  The measures the researcher used to assess the 
intervention helped reduce clinical significance (Julian, 2011) for state anxiety, but exceeded the 
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cutoff score of 39 once the intervention was removed.  During the follow-up interview, the 
participant mentioned that she would receive future preventative maintenance treatments going 
forward.  Given the effects of hand holding with a secure attachment for this participant, the 
participant was encouraged to use hand holding to reduce state anxiety during treatment.   
Participant Three 
 Given the results for participants one and two, the researcher measured participant three 
using an A-B design.  The same condition as that of participant two—of completing the CT scan 
meeting before treatment—was present for participant three.  Participant three was unique in the 
fact that he was diagnosed with PTSD.  Myers, Vanmeenen, and Servatius (2012) found that 
individuals with PTSD have higher trait anxiety than those without PTSD symptoms.  Thus, the 
researcher identified this participant as a valuable addition to the study as an expected stable and 
higher trait anxiety could provide a good baseline comparison.  In evaluating research questions 
one and two, the participant’s trait anxiety revealed an increasing trend across all baseline 
measures, but a decreasing trend in the intervention phase.  The participant’s state anxiety 
revealed a minimally decreasing trend in the baseline and a moderate decreasing trend in the 
intervention phase.  As participant three has PTSD, the researcher expected the trait anxiety of 
the participant to remain higher than that of the previous participants (Myers et al., 2012).  
However, using the intervention of hand holding with a secure attachment did not yield the 
expected results.  Thus, for this participant, hand holding may produce effects even on trait 
anxiety during treatment.  Regarding the third research question, the data reveals that the 
baseline measures of state anxiety were above the cutoff score of 39 and measures in the 
intervention phase were all below the cutoff score of 39 (Julian, 2011).  The researcher deemed 
scores below the cutoff of 39 clinically significant (Julian, 2011).  Concluding the follow-up 
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interview, the researcher explained to the participant that given the immediate effect the 
intervention had on the participant, it appears the study was beneficial and the researcher 
recommended that the participant use hand holding for future, preventative treatments.   
Implications for Practice and Future Research 
 In the context of extant research, the findings of this dissertation have significant 
implications with regard to the effects of cancer patients’ anxiety while holding hands with a 
secure attachment.  Overall, the results indicate that hand holding is an effective intervention to 
reduce the anxiety of non-Hodgkin’s lymphoma patients during treatment.  This study’s findings 
align well with those of previous research focused on the importance of secure attachment 
relationships and the effects of hand holding on anxiety reduction (Adler & Page, 2008; 
Ainsworth, 1973; Barre et al., 2015; Bowlby, 1969; Ergott, 2008; Johnson et al., 2013; Maresh et 
al., 2013; Moon & Cho, 2001; Oh & Park, 2004; Pirbudak & Tepe, 2017; Weeks et al., 1993).  
Further, as there is a growing need to address cancer patient anxiety during treatment (Barre et 
al., 2015; Oerlemans et al., 2014), and hand holding may be effective in reducing patient anxiety 
and assist in physical adaptation to cancer treatment (Parham, 2009).  
 As Armitage et al. (2017) estimated in 2016, roughly 72,580 cases of non-Hodgkin’s 
lymphoma would arise in the United States alone; these patients are likely to experience 
significant psychological effects throughout treatment.  Many patients are curious about their 
diagnosed form of non-Hodgkin’s lymphoma and discover informative but frightening statistics, 
such as the fact that patients have a five-year survival rate of 70% and a ten-year survival rate of 
60% (American Cancer Society, 2016b).  Chemocare (2018) has summarized the anxiety any 
cancer patient generally experiences as including: uneasiness, nervousness, worries, and/or fear 
in relation to the diagnosis of cancer and treatment.  In addition to the diagnosis and realization 
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of the disease, Oerlemans et al. (2014) revealed that 48.7% (N = 300) of cancer patients 
experience anxiety throughout treatment.  Research seeking to assist the psychological needs of 
lymphoma cancer patients, specific to anxiety and depression reduction during treatment, was 
exceeding 15 years. Thus, the results of this dissertation sought to update research in this area 
and emphasize the importance and impact of hand holding as an effective intervention to assist in 
patient anxiety reduction.   
 This dissertation built upon the intervention foundations, but under separate conditions, 
of studies by Ergott (2008), Johnson et al. (2013), Pirbudak and Tepe (2017), and Nicholls et al. 
(2014).  Ergott (2008) and Pirbudak and Tepe (2017) focused on hand holding to reduce patient 
anxiety in different settings, but did not focus on the use of a secure attachment’s presence.  With 
regard to the baseline and intervention phases, each participant selected an individual who could 
attend each measure and with whom they felt an emotional bond.  All participants in the present 
study chose their spouse as the secure attachment.  Results of these studies (Ergott, 2008; 
Johnson et al., 2013; Pirbudak & Tepe, 2017; Nicholls et al., 2014) and this dissertation appear 
similar in terms of patient anxiety reduction.  Nicholls et al. (2014) found that general patients in 
the medical field (non-cancer specific) experienced positive effects to their wellbeing when a 
secure attachment is present during treatment.  The results of this dissertation may indicate that a 
secure attachment being present during treatment produces an equitable impact on patients as the 
Nicholls et al. (2014) identified, but specific to a cancer setting.  However, when compared to 
adding the intervention of hand holding, the presence of a secure attachment did not produce as 
significant an effect on patient anxiety.  Specifically, this study showed that the addition of hand 
holding with a secure attachment effectively lowered anxiety on a greater scale.  Johnson et al. 
(2013) combined the presence of a secure attachment with hand holding to measure brain 
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activation when triggered by a threat.  Results produced a greater reduction of fear and anxiety 
when holding hands with a secure attachment than with a stranger (Johnson et al., 2013).  While 
the dependent variable was different in the Johnson et al. (2013) study and this dissertation, both 
studies indicate positive effects in anxiety reduction when holding hands with a secure 
attachment during an anxiety-triggering event.  Comparatively to the Johnson et al. (2013) study, 
this dissertation furthered the field of knowledge in the effectiveness of hand holding with a 
secure attachment within a different threatening environment.  
  Oncology care teams (OCT) and mental health professionals (MHP) could apply the 
results of this dissertation within their treatment care.  Under the care of OCT’s and MHP’s, non-
Hodgkin’s lymphoma patients can be more informed about anxiety reduction throughout 
treatment.  Specifically, any OCT that comes into contact with non-Hodgkin’s lymphoma 
patients, and potentially other cancer patients with different disease types receiving treatment, 
can offer the intervention of hand holding with a secure attachment as a useful method to lower 
anxiety during treatment.  Oncology care teams may choose to inform non-Hodgkin’s patients 
who demonstrate anxiety tendencies or have a previous diagnosis of anxiety of the positive 
effects of hand holding with a secure attachment during treatment.  Oncology care teams should 
ensure that patients have ample space to hold hands with the secure attachment during treatment, 
and continually assess the effectiveness of the intervention across other cancerous disease 
treatments.   
Mental health professionals who are counseling non-Hodgkin’s lymphoma patients can 
also review these results and suggest the intervention as a coping mechanism during treatment.  
Also, knowing that the presence of a secure attachment during treatment can offer moderate state 
anxiety reduction, while hand holding with a secure attachment during treatment can provide 
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more significant anxiety reduction, provides the patient with options in case hand holding is not a 
first choice.  Some participants may not be open to holding hands and even holding hands during 
treatment.  Given the various designs used, results indicate that hand holding can be effective if 
used at the beginning of treatment, towards the end of treatment, or throughout treatment.  
Therefore, if a patient consults a MHP at any point in time throughout treatment, the results of 
this study would be useful in educating the patient.  Finally, MHP’s who utilize talk-therapy and 
other forms of processing can reflect on the secure bond created with the secure attachment 
during treatment.  This could further enrich their secure attachment relationship and potentially 
continue to impact the effects of hand holding during treatment.  Additionally, the MHP may 
help the patient process what the secure attachment experienced while holding hands with the 
patient, so that the patient may feel more comfort and less of a burden, if such feelings are 
present.  Reflecting on the treatments with a MHP may also be beneficial for the patient to 
process to help identify when they might feel more anxiety.   
The results of this study may lead to future investigations of extending awareness of non-
Hodgkin’s lymphoma patients’ anxiety experienced outside the treatment setting, and thus, begin 
to have an effect on the trait anxiety of patients.  Patients reading statistics about their diagnosis 
and prognosis, for example, may feel additional stress and anxiety related to quality of life 
outside the treatment setting (American Cancer Society, 2016b; Nayak et al., 2017).  Therefore, 
building research on useful interventions for OCT’s and MHP’s may help in the overall systemic 
care of patients during treatment and in daily life living with cancer.    
 In addition to the suggestions for guided awareness OCT’s and MHP’s can provide, the 
results of the present study have a number of implications for future research.  First, the sample 
size of the present study was small; future research should focus on other cancerous diseases that 
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offer a potential for a larger sample size such as lung or breast cancers.  Second, it would be 
helpful in visual and statistical analysis to utilize a single-case design.  Importantly, every 
cancerous disease is treated differently and patients receive a varying number of treatments.  
Thus, researcher control is of high importance.  If allowable, the use of an ABAB design may 
offer valuable data to extend the effectiveness of hand holding during cancer treatment.   
 Ray (2015) explained that single-case designs are viable for researchers who wish to 
contribute valuable information on intervention effects.  The use of the various single-case 
designs in this study assisted in revealing specific participant results while also providing 
generalizable results (Adler & Page, 2008; Kazdin, 2011; Ray, 2015).  This study differs from a 
case study in that there is a focus on the manipulation of the independent variable, which leads to 
causal inference linking treatment effectiveness (Ray, 2015).  By allowing the researcher to 
manipulate the independent variable for participant one’s design, specific conclusions were 
discovered, which allowed for continued manipulation for the remaining participants’ designs.  
Therefore, future research should continue to investigate cancer patients’ mental health 
throughout treatment, including other forms of effective interventions to aid in systemic patient 
comfort.    
 At the conclusion of each participant’s measures, an unstructured interview was 
conducted.  The purpose of the interview was to help identify commonalities and differences 
between participants.  Participants expressed the positive effects hand holding offered in 
reducing their anxiety.  Future studies should design a structured interview focusing on the 
benefits of hand holding throughout the course of treatment.  This can help identify specific 
commonalities and differences between participants. 
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Limitations 
 The limitations of this study primarily relate to the treatment regimen length designed by 
the participants’ oncologists based on their diagnosis, biological factors, and environmental 
factors.  Each non-Hodgkin’s lymphoma participant in the present study underwent six 
chemotherapy measures.  The modifier for the study is the chemotherapy.  The participant’s 
diagnosis of non-Hodgkin’s lymphoma is a result of increased deregulation of cellular 
development.  Although participant selection was based on the Participant Screening Form 
(Appendix D), variables related to a patient’s genetics are beyond the control of the researcher.  
Patients were not required to submit cardiovascular records or any other genetic related medical 
records.  It is also beyond the researcher’s control if a patient receives a port for infusion or 
elects for intravenous (IV) therapy, as this is often based on patient preference.  Thus, if a patient 
chooses an IV each chemotherapy session, the patient runs the risk of “burning out” or 
“blowing” a vein, which might impact the patient’s selection of hand to hold and the hand 
holding experience in general.  Each participant utilized a port to receive treatment, and no 
variation occurred to the researchers knowledge.  Future studies could limit participant selection 
to only those that have a port to avoid this complication.  
 Participants’ STAI (Speilberger et al., 1983) responses were recorded by the participants’ 
secure attachments.  The goal of this recording approach was to help ensure honest responses, as 
cancer participants may have not felt well enough to take the time to respond accurately during 
treatment.  Thus, the secure attachment was able to read the questions, multiple times if needed, 
to the cancer participant.  Each STAI (Speilberger et al., 1983) is intended to represent the 
participant’s day-to-day anxiety levels.  One might assume that looking forward to the 
completion of treatment may impact a participant’s anxiety levels; thus, the goal was to measure 
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during the treatment and focus on the treatment time itself.  Therefore, the Post Session 
Questionnaire (Appendix F) was used to explain imprecisions that occurred.  Participants and 
secure attachments became frustrated at times having to repeat questions or ask to repeat 
answers.  Thus, in scoring the results, the researcher discovered scribbles over ratings to circle a 
different rating.  Further, maturation could be attributed in the same assessment being delivered.  
Future studies may want to randomize who reads and completes the assessment across the study.   
For the purposes of this study, the researcher used the Post Session Questionnaire 
(Appendix F) to explain possible variables to treatment and results.  However, a limitation was 
present in that whether or not participants were receiving individual mental health services was 
not included within the Post Session Questionnaire (Appendix F).  Realizing this viable 
information midway through data collection, the researcher reviewed each participant’s medical 
notes and did not find any evidence that mental health treatment was ongoing.  The medical 
notes containing this information were under the same technology portal referred to in chapter 
three.  This information would have been important to document in case a participant was 
implementing coping skills during treatment in addition to the intervention or during the baseline 
phase.  Each patient being treated with chemotherapy may have been experiencing various, 
unaccounted-for side effects, and may have been responding differently to the drugs.  Moreover, 
some of the drugs administered cause an anti-depressant effect, but these results vary depending 
on the patient.  It was also beyond the researcher’s control if the patient became ill during 
treatment, needed to exit to use the bathroom, switch hands to hold during treatment, walk about, 
or any other situation that would cause the participant to exit their treatment room.  However, 
every effort was made to maintain stability and consistency through recordings on the Post 
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Session Questionnaire (Appendix F).  Future studies should create a questionnaire for each 
measure that accounts for these more explicitly to maintain research consistency.  
Single-Case Designs and Analysis 
A single-case study design with a withdrawal / reversal design, such as ABAB (Ray, 
2015) for all participants would provide more evidence of treatment effects; however, given the 
limited treatments within the participants’ total treatment regimen for non-Hodgkin’s lymphoma, 
the researcher determined that designs of B, A-B, and B-A would offer a better comparison.  
While the researcher’s goal was to obtain more participants within each design, the target 
population of non-Hodgkin’s lymphoma patients offers a smaller pool of candidates compared to 
other cancer types.  Thus, future studies should open enrollment to various cancer types 
receiving treatment.   
Ray (2015) explained that, to enable an intervention to have a lasting effect, a study 
design should end with the intervention, rather than the control period.  To end the study with a 
withdrawal of the intervention may impede lasting effects of the intervention (Ray, 2015), as 
shown in participant two’s results.  In the event that the participants’ cancer returned, the effects 
of reduced anxiety could be beneficial for future treatment.  While participant two was measured 
under a B-A design, the researcher discussed with the participant that hand holding should be 
used for the remainder of her potential preventative treatments.  Unfortunately, the remainder of 
the treatments could not be measured to see if hand holding had an immediate effect again, as the 
timing and administration of the preventative treatments were inconsistent with those of the 
previous measures.  Therefore, future studies should focus on completing treatments with the 
intervention active.  Participant two was also taking medication for anxiety reduction (see 
methodology).  This may account for her consistently lower trait anxiety scores and should be 
98 
considered as a variable in future studies.  Lastly, the A-B single-case study design is considered 
more limited due to internal validity threats and lack of control for history without a reversal 
design such as an ABAB design (Ray, 2015).  While the use of an ABAB design would have 
been desirable, the minimum required measures the ABAB design would require would be 12 
(three per phase) treatments.  Given this limitation, the researcher suggests that by searching for 
other cancer types, there may be more treatments required to combat the disease.  Most patients 
with non-Hodgkin’s lymphoma only undergo six chemotherapy treatments.  To meet the 
requirement of inferential statistics, normality of distribution and independence of observations 
must be obtained (Ray, 2015).  The normal distribution in this case was negatively affected due 
to the minimal time points recorded and that measures were recorded on a weekly basis for 
participant three (Ray, 2015).  Participants one and two were assessed daily and may account for 
differing variation of state and trait scores.  Given participants different time frame of a 
measurement once a week, this may also account for the given trends for state and trait.  Given 
this limitation, the researcher decided to include both the both the PND and PAND as forms of 
statistical analysis.   
As mentioned previously, there is a lack of clear evidence as to which statistical analysis 
is best for single-case study designs (Shadish et al., 2008; Smith, 2012).  Thus, the researcher 
chose visual analysis to display significant results, determine a cutoff score for state anxiety, and 
measure the effect size using both PND and PAND (note: PND and PAND were only used for 
participants two and three as participant one did not have a baseline).  While the researcher 
considered other methods of analysis, many had stipulations this study could not meet due to the 
limited amount of treatments given to participants.  
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Intervention   
There are also a few limitations to consider when the participant is holding hands with 
the secure attachment.  First, at times there was limited space for the secure attachment to sit at 
one of the oncology sites.  This made it uncomfortable for the secure attachment to stretch across 
to hold hands.  This was only an issue for participant three, which was noted in the Post Session 
Questionnaire (Appendix F).  Thus, future studies may inquire about participants receiving 
ample space or their own treatment room/area to complete the hand holding measures under the 
STAI (Speilberger et al., 1983).  Finally, oncology staff at times required the participants’ arm to 
check vitals, which required the breaking of hand contact.  This was an issue for participant one.  
While this was not ideal, participant health understandably takes precedent.  This was also 
recorded in the Post Session Questionnaire (Appendix F) as necessary.  Including a questionnaire 
that accounts for the aforementioned could help conclude if there was an impact on anxiety 
caused by extraneous variables.     
Summary 
Individuals undergoing treatment for non-Hodgkin’s lymphoma can experience 
emotional distress impacting their quality-of-life (Adler & Page, 2008, American Cancer 
Society, 2016b).  The purpose of this dissertation was to focus on the mental and emotional 
effects experienced during treatment as limited research has been conducted.  Specifically, this 
study aimed to reduce the anxiety experienced during treatment for non-Hodgkin’s lymphoma 
when holding hands with a secure attachment.  Holding hands to reduce patient anxiety has been 
effective in other treatment settings (Ergott, 2008; Pirbudak & Tepe, 2017).  Thus, introducing 
the intervention of hand holding was selected to address the aforementioned problem non-
Hodgkin’s lymphoma patients experience.  
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Results from all participants revealed state anxiety scores at or below the cutoff score of 
39.  Using visual analysis, the researcher determined that participant one displayed a decreasing 
trend in state and trait anxiety when utilizing hand holding with a secure attachment.  Participant 
two experienced a decreasing trend in state anxiety and a minimally increased trend in trait 
anxiety with the use of hand holding with a secure attachment.  State anxiety greatly increased 
moving into the baseline measures, but gradually declined even within the baseline measures.  
Trait anxiety displayed a moderate increase in the absence of the intervention.  Participant 
three’s state and trait anxiety decreased immediately following the introduction of the 
intervention.  Given these findings, the use of hand holding with a secure attachment during 
treatment for non-Hodgkin’s lymphoma patients might be an effective immediate intervention to 
decrease state anxiety and gradually decrease trait anxiety.  Future research is warranted across 
different cancer disease types.  This study can therefore function as a pilot study for future 
single-case designs, and eventually larger experimental designs.  
Given the variability in each participant’s treatment of non-Hodgkin’s lymphoma, the use 
of a single-case design proved useful in recording specific and meaningful information.  
Moreover, the benefit of single-case designs is using a small sample size, which allows each 
participant to function as their own control (Ray, 2015).  Future research should focus on using 
one single-case design, and specifically finding cancer patients whose treatment regimen exceeds 
six sessions in order to record more data.   
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APPENDIX C 
Informed Consent 
 
Investigator: West Loveland, M.S., LMFT, LPC (AR, MO) 
  University of Arkansas 
  479-366-2308     wrlovela@uark.edu 
Faculty Advisor:  David Christian, Ph.D., LPC 
        University of Arkansas 
        479-575-3329    ddchrist@uark.edu      
Description: The purpose of this study is to explore how the anxiety levels of patients receiving 
treatment for non-Hodgkin’s lymphoma are affected while holding hands with a secure 
attachment.   
Research Question: How is a patient’s anxiety affected during treatment when holding 
hands?  
Measurement: State Trait Anxiety Inventory (Spielberger et al., 1983).  
Future Plans: This study also aims to create future research integrating hand holding 
with other forms of cancer.  
Number of subjects: A maximum of 10 participants will be selected. There are four 
groups. You will be placed in a group randomly. 
 
Procedures:  
Cancer patient.  Seeking up to 10 non-Hodgkin lymphoma participants. They each will 
select their own secure attachment. A secure attachment can be a loved one, family member, 
friend, etc. The primary investigator and/or a sub-investigator will inform the patient of the 
study, and offer the chance to participate. If the patient is interested they will consent to give the 
sub-investigator their contact information (e-mail and phone number). The sub-investigator will 
contact them via e-mail and/or phone to discuss the informed consent and Participant Screening 
Form. If the patient wants to be a part of the study, they will sign and date the informed consent 
in person before their first treatment.  
Enrollment: The study only has open enrollment for two months, in order to ensure that 
participants begin the study within a close time frame.  The researcher in this study also serves as 
a sub-investigator and Dr. Pat Travis as the primary Investigator.   
Secure attachment.  Once accepted into the study, the sub-investigator will contact the 
secure attachment provided by the patient on the Participant Screening Form by phone.  The 
researcher will call to explain the informed consent and Participant Screening Form. If the secure 
attachment wants to be a part of the study, they will sign the informed consent and Participant 
Screening Form when they arrive with the cancer participant. The Secure Attachment Protocol 
Form is only for the secure attachment to review and sign. This will help ensure accurate 
recording of results. This will be signed along with the previous forms.  
Data Collection:   
• Upon acceptance into the study, each participant is required to sign the informed consent 
and complete the Participant Screening Form in person.  
• The cancer patient (participant) will select a secure attachment. 
• The secure attachment will complete the Secure Attachment Protocol Form to review and 
sign in person. 
• Treatment will begin as scheduled by the oncologist.  
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• Participant 1 will go through all treatments and the CT results meeting without 
holding hands. 
o Your secure attachment person will attend each treatment. 
o The secure attachment will read the STAI to you and record answers 30 minutes 
after the start of treatment. 
 The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
 The STAI will be given after your CT scan meeting with your oncologist 
midway through treatment. That is after treatment 3 and before treatment 
4.  
o After each STAI, participants will complete the Post Session Questionnaire. This 
will explain any influence on your anxiety.  
o All results will be collected. 
• Participant 2 will go through all treatments and the CT results meeting while 
holding hands. 
o Your secure attachment person will attend each treatment. 
o The secure attachment will read the STAI to you and record answers 30 minutes 
after the start of treatment. 
 The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
 Hold hands with your secure attachment throughout every treatment. 
 The STAI will be given after your CT scan meeting with your oncologist 
midway through treatment. That is after treatment 3 and before treatment 
4.  
 Hold hands with your secure attachment during the meeting. 
o After each STAI, participants will complete the Post Session Questionnaire. This 
will explain any influence on your anxiety.  
o All results will be collected. 
• Participant 3 will go through the first 3 treatments and the CT results meeting 
holding hands. The last 3 treatments you will not hold hands during treatment.  
o Your secure attachment person will attend each treatment. 
o The secure attachment will read the STAI to you and record answers 30 minutes 
after the start of treatment. 
 The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
 Hold hands with your secure attachment for treatments 1, 2, 3.  
 Do not hold hands with your secure attachment during treatments 4, 5, 6.  
 The STAI will be given after your CT scan meeting with your oncologist 
midway through treatment. That is after treatment 3 and before treatment 
4.  
 Hold hands with your secure attachment during the meeting.  
o After each STAI, participants will complete the Post Session Questionnaire. This 
will explain any influence on your anxiety.  
o All results will be collected. 
• Participant 4 will go through the first 3 treatments and the CT results meeting 
without holding hands. The last 3 treatments you will hold hands during treatment.  
o Your secure attachment person will attend each treatment. 
o The secure attachment will read the STAI to you and record answers 30 minutes 
after the start of treatment. 
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 The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
 Do not hold hands with your secure attachment for treatments 1, 2, 3. 
 Hold hands with your secure attachment for treatments 4, 5, 6.  
 The STAI will be given after your CT scan meeting with your oncologist 
midway through treatment. That is after treatment 3 and before treatment 
4.  
 Do not hold hands with your secure attachment during the CT results 
meeting.  
o After each STAI, participants will complete the Post Session Questionnaire. This 
will explain any influence on your anxiety.  
o All results will be collected. 
Participants must be 18 years or older and have Lymphoma (Non-Hodgkin’s Lymphoma).  
 
Risks and Benefits: Potential risks include identifying negative relational patterns. Though this 
is unlikely. In the event participants develop negative feelings, a referral will be offered to a 
Licensed Mental Health Professional, and the participant may exit the study at any point. 
Benefits include strengthening your relationship with your secure attachment. You may also 
experience lower anxiety during treatment.  
  Note to participant: There is no guarantee this will aid in the overall treatment regimen. 
  
Compensation: By participating in this study to completion, you will receive a $25 gift card. 
 
Voluntary Participation: You are free to refuse to participate in the research or to stop 
participating at any point. There are no negative consequences in exiting the study early. To 
receive the gift card, the participant must complete the study from start to completion.  
 
Confidentiality: All of your documents will be collected and stored in a secure location.  You 
will be assigned a participant code. All identifying information will be kept confidential to the 
extent allowed by state and federal law, Highlands Oncology Group, and the University of 
Arkansas policy. 
 
Questions: If you have any questions about the research, please feel free to contact me by email: 
wrlovela@uark.edu.  If you have questions or concerns about your rights as a research 
participant, you may contact the University’s IRB Coordinator, Ro Windwalker, 109 MLKG 
Building, 479-575-2208, irb@uark.edu. 
 
 
 
I have read and understand the provided information and have had the opportunity to ask 
questions.  I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason and without cost.  I understand that I will be given a copy of this 
consent form. I voluntarily agree to take part in this study. 
 
Participant’s signature: _________________________________Date: ____________________ 
 
Investigator’s signature: ________________________________ Date: ____________________ 
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APPENDIX D 
Participant Screening Form 
 
Participant ID#:_________________________ 
Gender:__________________________ 
Relationship Status: 
 ____ Single 
 ____  Dating 
____  Married 
 ____  Divorced 
 ____  Widowed 
 ____  Remarried 
 
Ethnicity: 
____  African American        
____ American Indian or Native American      
____ Asian or Pacific Islander            
____  Caucasian, Non-Hispanic       
____  Hispanic or Latino       
             ____  Middle Eastern              
____  Bi/Multiracial (list) _______________________                  
____  Other __________________________________   
   
Cancer Type:         Non-Hodgkin’s 
 
Stage of Diagnosis (Circle one):     1            2             3            4 
 
 
Please circle “yes” or “no” in response to the questions below. Then, please respond to the next 
question. Once the Research Acceptance Form is collected, you will be contacted if appropriate 
for the study. Thank you for your consideration to be a part in this study. 
 
 
Have you been through chemotherapy before for the treatment of non-Hodgkin’s lymphoma or 
another type of cancer/illness? 
 
YES   NO 
 
 
Can the same caretaker, loved one, significant other, etc. be at each treatment administered for 
the purpose of this study?  
  
YES   NO 
 
 
If NO, explain why one caretaker, loved one, significant other, etc. cannot be at each treatment.   
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______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
  
Do you and the selected caretaker, loved one, significant other, etc. have a secure attachment? 
Secure attachment, as defined in this study, is the enduring emotional bond that a person feels 
with another that results in the ability to manage anxiety. 
 
YES   NO 
 
 
If NO, explain why caretaker, loved one, significant other, etc. is not a secure attachment.   
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
Does holding hands with the secure attachment create anxiety for you? 
 
YES   NO 
 
 
If YES, explain why.   
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
Signature: 
 
 
Date: 
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APPENDIX E 
Secure Attachment Protocol Form 
 
Thank you for your participation in this research. Please read through the Secure Attachment 
Protocol Form. It is very important that you follow this form throughout the study to help ensure 
accuracy and reliability.  
 
Requirements of Chosen Secure Attachment: 
• To attend each chemotherapy treatment  
• To complete the State-Trait Anxiety Inventory each appointment assigned 
• To complete the Post Session Questionnaire each appointment assigned 
• For those in groups two, three, and four ONLY 
o You will hold the hand of the cancer patient for the entirety of the chemotherapy 
session. Record any deviation or breaking hand holding in the Post Session 
Questionnaire 
o Hold hands with your non-writing (not dominate) hand  
 
Please follow the designated group you are assigned. 
 
Participant one. Group one went through all seven measures without holding hands.  A detailed 
protocol is listed below that group members followed based on the informed consent.  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment. 
3. The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
4. The STAI will be given after your CT scan meeting with your oncologist midway 
through treatment.  That is after treatment 3 and before treatment 4.  
5. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
6. All results will be collected. 
Participant two. Group two went through all seven measures while holding hands.  A detailed 
protocol is listed below that group members followed based on the informed consent.  
1. Your secure attachment person will attend each treatment. 
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2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment. 
3. The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
4. Hold hands with your secure attachment throughout every treatment. 
5. The STAI will be given after your CT scan meeting with your oncologist prior to 
starting treatment.  
6. Hold hands with your secure attachment during the meeting. 
7. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
8. All results will be collected. 
Participant three. Group three went through the first four measures holding hands.  The last 
three measures, the participant did not hold hands.  A detailed protocol is listed below that group 
members followed based on the informed consent.  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment. 
3. The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
4. Hold hands with your secure attachment for treatments 1, 2, 3.  
5. Do not hold hands with your secure attachment during treatments 4, 5, 6.  
6. The STAI will be given after your CT scan meeting with your oncologist prior to 
starting treatment.  
7. Hold hands with your secure attachment during the meeting.  
8. After each STAI, participants will complete the Post Session Questionnaire.  This will 
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explain any influence on your anxiety.  
9. All results will be collected. 
Participant four. Group four went through the first four measures without holding hands.  The 
last three measures, the participant was instructed to hold hands.  A detailed protocol is listed 
below that group members followed based on the informed consent.  
1. Your secure attachment person will attend each treatment. 
2. The secure attachment will read the STAI to you and record answers 30 minutes after 
the start of treatment. 
3. The STAI will be given at treatment 1, 2, 3, 4, 5, and 6.  
4. Do not hold hands with your secure attachment for treatments 1, 2, 3. 
5. Hold hands with your secure attachment for treatments 4, 5, 6.  
6. The STAI will be given after your CT scan meeting with your oncologist prior to 
starting treatment.  
7. Do not hold hands with your secure attachment during the CT results meeting.  
8. After each STAI, participants will complete the Post Session Questionnaire.  This will 
explain any influence on your anxiety.  
9. All results will be collected. 
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APPENDIX F 
Post Session Questionnaire 
 
 
Please complete this form following the State-Trait Anxiety Inventory. Return this form and the 
State-Trait Anxiety Inventory to your nurse or the front desk.  
 
1. Please explain any life altering events that have occurred in the past three weeks (since 
your last treatment) that may impact your mood today. 
 
 
 
 
 
2. Please describe how has your relationship with your secure attachment been since your 
last treatment. Are there any conflictions that have impacted your mood today?  
 
 
 
 
 
3. At any point during treatment, did you break hand contact leading up to the State-trait 
Anxiety Inventory? If so, please explain why. 
 
 
 
 
 
4. Please explain any deviation from the Secure Attachment Protocol Form. 
 
 
 
 
 
5. Please explain how you feel holding hands during treatment. 
 
 
 
 
 
 
 
 
 
 
